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ABSTRACT  
 
Michael L. Washburn 
Modeling HCV infection, immunopathogenesis, and therapy in humanized mice 
 (Under the direction of Dr. Lishan Su) 
 
Approximately 170 million people worldwide are chronically infected by the 
hepatitis C virus (HCV), which is often associated with impaired T cell responses to viral 
antigens, chronic liver inflammation, fibrosis/cirrhosis, and hepatocellular carcinoma.    
Current therapies for HCV are limited by low efficacy and detrimental side-effects, 
leaving many patients with poor quality of life.  Understanding HCV infection, 
immunopathogenesis, and development of improved therapies for HCV is hampered by 
the lack of a robust model system.   
In this dissertation, I establish a novel humanized mouse model to study HCV 
infection, immunopathogenesis, and therapies to overcome the immune tolerance, liver 
inflammation, fibrosis, and liver cancer that characterize HCV infection.  To achieve this 
goal, I first established a mouse model to study persistently expressed foreign antigens in 
the liver by infection with liver tropic adeno-associated virus (AAV) vector.  I 
demonstrated that expressing LIGHT with an adenovirus vector (Ad) in mice with 
established AAV vectors in the liver led to clearance of the AAV, correlating with 
enhanced CD8 effector T cells in the liver and inflammation.  Interestingly, Ad-LIGHT 
cleared AAV but caused no significant liver inflammation in LTβR-null mice.  These 
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findings shed light on developing novel immuno-therapeutics to treat people chronically 
infected with hepato-tropic viruses.    
 I next developed an improved humanized mouse model designed to study human 
hepato-tropic viruses and their interaction with both the human immune system and liver.  
I created transgenic Rag2-/- γc-/- mice with the FKBP-caspase 8 fusion gene expressed 
from the albumin enhancer/promoter (AFC8/DKO).  Inducible apoptosis of mouse 
hepatocytes enables transplanted human hepatocyte progenitor cells (Hep) and CD34+ 
hematopoietic stem/progenitor cells (HSC) to selectively repopulate the liver and thereby 
providing us with a highly functional mouse model containing a human immune system 
and liver.  
Finally, I showed that AFC8/DKO mice, transplanted with human Hep and HSC 
(AFC8/DKO-hu HSC/Hep), are susceptible to HCV infection.  I further demonstrate that 
the mice develop a human immune response to HCV, leading to liver fibrosis.  The 
AFC8/DKO-hu HSC/Hep mouse model will greatly advance the study of HCV infection, 
immunopathogenesis, and development of improved therapies to combat infection and 
liver disease progression.   
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HCV infection is a huge global health problem 
 
Worldwide prevalence 
HCV infection poses a huge health problem worldwide.  One of the most 
troubling aspects of the virus is its asymptomatic nature.  Since symptoms of the virus are 
not always identifiable, the nearly 170 million people who are infected might not be 
aware of it for years (1),  which makes controlling the spread of the virus very 
challenging.  Compounding the problem is the fact that HCV is primarily transmitted 
through intravenous drug use (1) and those affected would not know to limit this risky 
behavior to inhibit spread of the virus.  Upon infection with HCV, 60-90% of individuals 
have chronically evolving hepatitis infection, of whom 20%  progresses to liver cirrhosis, 
hepatocellular carcinoma (HCC), and death (1, 2).  As a result of the significant liver 
disease caused by the virus, HCV is the leading cause of liver transplantation in the 
United States and Europe (3), underscoring its importance as a global health problem. 
 
Prevention and treatment shortcomings 
Although recognizing symptoms of HCV infection to prevent spread of the virus 
is a problem, the ability of the virus to both inhibit and evade host immune responses is a 
far greater threat to controlling infection and disease progression.  There is no preventive 
vaccine available for HCV and it is likely that there will not be one created for some 
time, if ever, in part due to the ability of HCV to mutate and escape the immune response. 
Once a persistent infection has been established in a person, there is some hope for 
clearance of the virus through therapy.   The current standard-of-care for treating HCV is 
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pegylated interferon-α and ribavirin combination therapy, which leads to clearance of the 
virus and sustained virologic response  in about 50% of individuals, depending on the 
HCV genotype (HCV genotype 1 is the most difficult to eradicate with this therapy) (4, 
5).  However, this is far from complete efficacy and is often associated with significant 
toxicity.  Therefore, there is an urgent need for improved therapies to combat this elusive 
virus.  
 
Immune responses to HCV 
 
Innate immune response 
The first defense against viral infections is the innate immune response, which 
incorporates both patrolling immune cells that directly combat the virus as well as 
activation of genes within infected cells.  The secretion of type 1 interferons (IFN), 
primarily by plasmacytoid dendritic cells (pDC), is a crucial component of the initial 
innate immune response against viruses (5).  Interestingly, the frequency of pDC’s and 
their ability to produce IFN is dramatically reduced in the blood during acute HCV 
infection, which inversely correlates with increased liver damage (6).  While the 
mechanism for the reduced frequency and function of pDC’s during HCV infection is not 
clear, it is evident that the virus has evolved to interfere with the potent anti-viral effects 
of IFN.  However, other reports have detected no pDC alteration during HCV infection 
(7).  The confusion is due to the difficulty of studying pDC’s in lymphoid organs in HCV 
infected patients, and highlights the urgent need of a suitable HCV animal model.    
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In addition to pDC’s, natural killer (NK) cells are early responder cells to HCV 
infection.  NK cells promote recruitment of inflammatory cells to the site of infection (8), 
produce IFN-γ to combat viral replication, and can directly kill infected cells (9).  Once 
NK cells are activated, they are able to recruit help from the adaptive immune system to 
combat HCV by stimulating maturation of dendritic cells (DC) (10).  However, NK cells 
in HCV infected patients are often impaired in function (11), allowing the virus to 
establish an infection in the host.  
 
Intracellular innate immune response 
If HCV is able to avoid the initial onslaught from the immune system and 
establish an infection, there are significant transcriptional changes that occur in type 1 
IFN-response genes in the infected cell within the first few weeks of  infection (12).  The  
retinoic acid inducible gene (RIG-I) can recognize double stranded RNA (dsRNA) in an 
HCV infected hepatocyte, resulting in activation of interferon regulatory factor-3 (IRF-3), 
which in turn activates IFN-β, leading to production of several type 1 interferons (1).  
Interestingly, the NS3-4A protease of HCV is able to inhibit the activation of IRF-3 
through disruption of the carboxy-terminal phosphorylation of IRF-3 by RIG-I, allowing 
the virus to avoid the IFN response and continue to replicate in the liver (13). Toll like 
receptor 3 (TLR-3) also recognizes dsRNA and induces IFN through a signaling cascade 
mediated by interaction with TRIF.  However, HCV can also block this IFN induction 
mechanism by cleavage of TRIF with the NS3-4A protease (14).  The HCV core protein 
can also attenuate the IFN response to the virus by interfering with the JAK/STAT 
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pathway through induction of SOCS1/3 (15) and inhibition of STAT1 phosphorylation 
(16).  
 If HCV is not able to completely block the IFN response, the virus has evolved 
mechanisms to interfere with IFN-stimulated genes, such as 2’,5’ OAS and protein kinase 
R, through interaction with the NS5A and E2 protein of HCV (17, 18).  While the innate 
immune system has numerous mechanisms to fight off HCV infection, the virus has 
evolved to evade many of these responses, leaving the battle with HCV to the adaptive 
immune system.  
 
Adaptive immune response 
Providing the link between the innate and adaptive immune system are pDC and 
conventional monocyte-derived dendritic cells (mDC).  mDC’s reside in tissues 
throughout the body, and their ability to uptake and present foreign antigens enables them 
to activate T cells, which fight off viral infections (19).  The ability of mDC’s to function 
as efficient antigen presenting cells (APC) requires activation and maturation, which can 
be inhibited by HCV (20).  Disruption of the allostimulatory capability of mDC’s by 
HCV has been reported in some patient studies (21), but others have shown no 
correlation (22).  While the role of mDC’s in resolution of HCV infection is not clear, a 
broad, specific, vigorous, and sustained adaptive immune response with HCV specific T 
cells is essential in control and resolution of HCV infection (23). 
Even with production of IFN early in HCV infection by pDC’s, a vigorous T cell 
response is needed to clear HCV.  T cell responses to HCV are detectable 4-8 weeks after 
the onset of infection (24, 25), and correlate with a decrease in HCV RNA (26) and 
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spikes in alanine amino transferase (ALT) levels in the serum (24), suggesting an 
immune-mediated liver damage.  Concurrent with a decrease in viral titer is an increase 
of IFN-γ in the liver (26).  HCV-specific CD4+ T cells rapidly proliferate and produce 
IL-2 and IFN-γ in patients who go on to resolve the infection (27, 28), whereas a weak or 
short-lived response often leads to viral persistence (29).  Also critical to controlling 
HCV infection are CD8+ T cell responses.  Accumulation of HCV-specific CD8+ T cells 
in the blood and liver correlates with a reduction in HCV RNA (30), and these CD8+ T 
cells produce  IFN-γ and demonstrate cytotoxic T lymphocyte (CTL) activity to HCV 
peptides (31, 32).  However, these cellular immune responses are often not sufficient to 
deter HCV from establishing a chronic infection.   
 
Chronic infection and immunopathogenesis of HCV 
 
Establishing chronic infection 
While the innate immune responses are potent and broad enough to clear HCV in 
20%  infected individuals, the virus often persists and establishes a chronic infection 
nearly 80% of the time (2).  As an infection progresses towards chronicity, there is a 
decline in the numbers and function of T cells in the peripheral blood, as well a reduction 
in the number of viral epitopes that are recognized (33).  With nearly 1012 viral genomes 
being produced every day during a chronic infection, the high turnover rate of HCV and 
lack of  RNA polymerase proofreading leads to an abundance of mutations in the virion 
(34).  Mutations in viral epitopes recognized by human leukocyte antigen (HLA) class I 
and II prevent host recognition of the virus and impair the hosts ability to generate HCV-
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specific T cells.  Even with CD4+ and CD8+ HCV-specific T cells present during chronic 
infection, they display reduced effector functions with impaired ability to produce IL-2 
and IFN-γ (35, 36), further contributing to the persistence of HCV.   Regulatory T cells 
(Treg) have also been implicated in suppressing CD4+ T cell responses to HCV (37).  
Both frequency and function of Tregs are increased in patients who develop chronic HCV 
infection, compared with patients who clear the virus (38). 
Similar to what is observed in other persistent viral infections (39), HCV-specific 
CD8+ T cells display an exhausted phenotype (40).  T cell exhaustion is a characteristic 
of viral infections that initially produce large amounts of virus, then persist with high 
viral load (41).  HCV-specific CD8+ T cells often demonstrate an exhausted phenotype 
with reduced proliferation, cytotoxicity, and an up-regulation of programmed death -1 
(PD-1) (24, 42).  While it is not clear if this is due to viral factors inhibiting function of 
the cell, it is evident that HCV specific CD4+ T cells are required to rescue the defect in 
the CD8+ T cells (28, 32).  By providing help, CD4+ T cells assist CD8+ T cells in 
becoming effector memory T cells that recognize HCV antigens and produce cytokines to 
fight off infection.   
 
Immunopathogenesis in the liver 
Although a robust immune response is beneficial in preventing HCV from 
establishing a chronic infection, it can also result in liver damage.  During the acute stage 
of infection, activation of cellular immune responses to HCV results in spikes of serum 
liver transaminases, which indicate immune-mediated transient liver damage (24).  If 
HCV is able to evade in initial immune response and establish a chronic infection in 
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hepatocytes, it induces oxidative stress and a recruitment of inflammatory cells to the site 
of infection.  The lymphocytes infiltrate the liver and kill the infected hepatocyte by 
inducing apoptosis through FasL/Fas, perforin, and TNF receptors (43, 44).  It is 
proposed that repeated killing of infected hepatocytes leads to secretion of pro-fibrotic 
cytokines, including TGF-β, resulting in activation of hepatic stellate cells (SC).   
 
Liver disease progression 
SC are the primary cells involved in promoting liver fibrosis.  Activation of SC 
induces production of extracellular matrix (collagen), which indicates the initiation of 
liver fibrosis.  Platelet derived growth factor (PDGF) is a potent stimulator of SC (45), 
and  activated stellate cells can be identified by their expression of alpha smooth muscle 
actin (αSMA) (46).  HCV proteins have also been shown to directly induce activation of 
stellate cells and inflammatory signals (47).   
Upon initiation of fibrosis, collagen deposition is first observed around the portal 
veins throughout the liver, followed by fibrous strands extending away from the portal 
areas.  Matrix metalloprotenases (MMP) are enzymes that function to degrade collagen 
(48).  However, activated stellate cells produce tissue inhibitors of metalloprotenases 
(TIMP), which can inhibit MMP from degrading collagen, allowing for progression of 
liver fibrosis (49).   
As the liver disease advances, the fibrous areas around the portal regions expand 
and form bridges throughout the liver parenchymal space connecting the portal areas with 
collagen.  Advanced bridging fibrosis is characterized as cirrhosis and often leads to 
hepatocellular carcinoma (50). 
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HCV/HIV co-infection 
Due to similar routes of transmission, HCV is a major cause of morbidity and 
mortality among HIV infected individuals (51).  In the United States, several hundred 
thousand individuals are co-infected with these viruses, representing ~25% of HIV-
infected and ~10% of HCV-infected individuals (52).  Increased HCV RNA levels has 
been associated with progression to AIDS (53).  HIV-HCV co-infection also results in 
enhanced HCV replication, and HIV seroconversion correlates with increases in HCV 
viral load (54).  Disappointingly, anti-retroviral therapy to fight HIV infection causes 
increased HCV viral load and hepatotoxicity (55-59), and the increased viral load 
correlates with accelerated disease progression.   
Co-infected individuals often have advanced liver fibrosis and cirrhosis leading to 
earlier mortality than HCV mono-infected patients (60-68).  Since HIV primarily infects 
lymphoid tissues and HCV primarily infects hepatocytes, it is interesting how these 
viruses cooperate to advance liver disease progression.  A hallmark of HIV disease 
progression is depletion of CD4+ T cells, which provides an immunosuppressed 
environment (69).  Since CD4+ T cells are critical in controlling HCV infection, disease 
progression is accelerated (70).  Chronic HIV infection also induces persistent immune 
activation (71), which alters the cytokine milieu in the liver through accumulation of 
CD8+ T cells that produce pro-fibrotic cytokines, leading to chronic inflammation in the 
liver of co-infected individuals (72, 73).  In summary, through the chronic activation of 
the immune system and hepatic stellate cells, HCV infection often leads to liver fibrosis 
and cirrhosis.  HIV co-infection accelerates liver disease progression, which can result in 
hepatocellular carcinoma and death.  
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Liver as a unique lymphoid organ 
 
Multiple roles 
The ability of HCV to establish a chronic infection may also be aided by the 
distinctive properties of the liver.  In addition to being the primary site of infection of 
HCV, the liver encounters bacterial products and harmless food-derived antigens that are 
transported through the blood from the intestines.  The constant presence of both 
microbial molecules and harmless non-self antigens may result in the liver’s ability to 
activate an immune response or induce tolerance to the antigen.  Due to the presence of 
both harmless antigens and invading microbes, the liver must be able to distinguish 
between the two and act accordingly.   
 
Cell types in the liver and T cell tolerance 
The liver dendritic cells are the traditional cell type involved in processing antigen 
and presenting it to T cells to generate an immune response when needed.  Primed T cells 
are activated and destroy the invading bacteria or virus, as is generally the case in most 
infections, including hepatitis A virus (74).  However, T cell mediated immunity does not 
always clear the invading pathogen from the liver, resulting in persistent infection.   
Contributing to the unique immunological properties of the liver is the fact that 
antigen presentation in the liver is not strictly limited to DC’s.   Rather, nearly every cell 
type found in the liver has a role in antigen presentation.  Hepatocytes are the most 
abundant cell type in the liver and are responsible for 70-80% of the liver mass.  In 
addition to their functions in protein synthesis, bile secretion, and detoxification, 
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hepatocytes can act as APC’s (75).  However, the interaction of hepatocytes with T cells 
often leads to T cell tolerance to the antigen (76). 
Kupffer cells are the liver resident macrophages that are found throughout the 
hepatic sinusoids, but also are found in the space of the disse and make direct contact 
with hepatocytes (77).  While kupffer cells are able to present antigens to T cells to elicit 
an immune response (78), they are also implicated in inducing T cell tolerance to the 
antigen and weak immune responses (79).   
Liver sinusoidal endothelial cells (LSEC) are found throughout the liver and form 
the endothelial lining of the hepatic sinusoids.  They express several co-stimulatory 
molecules on their surface and thus appear to function as APC, capable of stimulating T 
cell responses (80).  T cells flowing through the blood in the liver often make contact 
with LSEC.  Rather than eliciting T cell activation through their interaction, LSEC often 
induce T cell tolerance and weak immune responses to the antigen (81). 
Hepatic stellate cells (SC) account for 5-8% of the total cells in a normal liver.  
They are located primarily in the space of the disse near periportal areas.  Under normal 
conditions, SC function as a storage cell for vitamin A.  Upon activation by numerous 
stimuli, notably HCV, they become activated and display a myofibroblast phenotype, and 
are critically involved in the progression of liver fibrosis and collagen deposition (82). 
Lymphocytes generally comprise 5-10% of the total cells in the liver.  NK cells 
are enriched in the liver relative to other lymphoid organs, and make up one third of the 
liver lymphocytes (83).  The remaining two thirds of lymphocytes are composed 
primarily of T cells, with higher numbers of CD8+ compared to CD4+ T cells (84).  
Tregs are also found in significant quantities in the liver and function to suppress immune 
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responses (85).  Although the liver is composed of various immune cells that can function 
to eliminate invading pathogens, these cells often induce T cell tolerance allowing for 
immune evasion by the pathogen.  
 
Organ transplant, GVHD 
Another unique property of the liver is its ability to induce immune-tolerance 
when transplanted into allogenic hosts, without the need for immunosuppressive drugs 
(86).  Other tissues, such as skin and kidneys, are rapidly rejected without constant 
immune suppression.  Further evidence for the unique toleragenic environment of the 
liver is seen in tumor studies.  Melanoma, breast, and lung tumors often metastasize to 
the liver, where they may be able to avoid detection by the activated immune system 
(87).  In summary, the liver possesses a distinct immunological environment that can 
allow for invading pathogens to avoid immune detection and clearance.  Viruses, such as 
HCV, are able to reside in the liver and establish a chronic infection by evading the 
immune response.   
   
Hepatic tolerance to AAV  
Induction of hepatic T cell tolerance is not unique to HCV.  Adeno-associated 
virus (AAV) vectors are a widely used tool for gene therapy and delivery (88), and 
hepatic transduction of AAV leads to T cell tolerance and persistent expression of AAV 
transgenes in the liver (89-92).  As a tool for studying gene delivery, AAV vectors have 
several advantages including; the ability to avoid inducing an innate immune response, 
persistence in the episome of a transduced cell for long-term expression, broad tissue 
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tropism, and efficient transduction of non-dividing cells, such as hepatocytes (93).  The 
mechanism of these viruses to evade host T cell responses and persist in the liver is not 
clear.  AAV vectors can impair T cells specific for the transgene (90, 94).  The functional 
impairment of CD8 T cells contributes to persistent foreign antigen expression from 
AAV vectors, similar to what is observed during HCV infection in humans. 
 
LIGHT/LTβR-HVEM signaling pathway 
 
T cell responses 
LIGHT (homologous to Lymphotoxins, exhibits Inducible expression, and 
competes with HSV Glycoprotein D for Herpesvirus entry mediator (HVEM), a receptor 
expressed by T lymphocytes) is a member of the TNF superfamily (TNFSF14) that 
interacts with the lymphotoxin beta receptor (LTβR) (95, 96) and HVEM (97, 98) 
receptors.  LIGHT has been reported to be a potent stimulator of T cell responses (99).  
Demonstrating this, ectopic expression of LIGHT in a tumor induces a massive 
infiltration of T cells, correlated with expression of chemokines, adhesion molecules, and 
rejection of established tumors at local and distal sites (100).  Additionally, injection of 
an adenoviral vector expressing LIGHT (Ad-LIGHT) into tumor tissue leads to 
generation of tumor-specific CTL and rejection of both established and disseminated 
metastasizing tumor cells in the peripheral tissues of mice (101).  Stimulation of the 
HVEM pathway with LIGHT enhances co-stimulation of T cell activation (102). By 
blocking the interaction of LIGHT with the LTβR or HVEM receptors, using a soluble 
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HVEM-Fc or LTβR-Fc fusion protein, the allogenic T cell responses and host-specific 
CTL responses are significantly reduced (103, 104).  
 
Role in the liver 
In the liver, LTβR is expressed on kupffer cells and may be involved in the 
process of T cell tolerance induction (105).  Additionally, the LTβR is also expressed on 
hepatocytes, where it contributes to liver regeneration and liver homeostasis (106).  In 
transgenic mice expressing LTα-β, blocking LTβR signaling reduced inflammation in the 
liver (107).   
The LTβR may also play a role in the ability of HCV to persist in the liver and 
cause liver damage.  It is reported that lymphotoxin β is upregulated in the liver of HCV 
infected patients (108), and that the HCV core protein directly interacts with LTβR, 
which may contribute to HCV-induced liver diseases (109). The HCV core - LTβR 
interaction induces NF-κB activation in most cells types and may be responsible for the 
chronic activation and persistent state of HCV infected cells (109-111).  Since the 
LIGHT/LTβR-HVEM signaling pathway is involved in modulation of immune responses 
in the liver, it may be a useful target in designing immunotherapies to clear a persistent 
viral infection in the liver.   
 
Animal models to study HCV  
 
Need for a better model system 
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The persistence of HCV as a global health threat is largely due to lack of an 
appropriate model system to study the virus.  To design and test specific therapies for 
HCV requires a model system that mimics the effects of the virus in humans.  The current 
standard-of-care treatment of ribavirin and pegylated IFN-α does not specifically target 
the virus, and is only effective in half of patients with poorly tolerated side effects (4).    
There is no preventative vaccine for HCV and efforts to test candidate vaccines are 
hampered by the lack of readily available animals for in vivo testing.  While there has 
been significant progress recently in developing cell culture models to study the HCV life 
cycle (112, 113), these models are limited by HCV strain and have limited usefulness for 
preventative or therapeutic vaccine testing.  Therefore, there is an urgent need for more 
efficacious and tolerable therapies against HCV that are validated in pre-clinical testing.  
To achieve this goal, an improved model system that allows for all aspects of HCV 
infection and disease progression to be studied is eagerly awaited. 
 
Chimpanzees  
Contributing to the deficiency of a readily available animal to study HCV is its 
limited species tropism.  HCV only infects humans and chimpanzees, and inconsistently 
the tree shrew tupaia.  However, tupaia are found only in the wild in Southeast Asia, 
resulting in significant heterogeneity between animals.  In addition, their immune system 
is poorly characterized, and the infection rate is low (114), leaving chimpanzees as the 
only reliable natural host for HCV that can be used for experimental testing.  Although 
the use of chimpanzees has provided insights into HCV infection, immunity, and disease 
progression (115), there are several drawbacks which limit their usefulness.  
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The availability of chimpanzees for research is severely limited, in part due to the 
significant costs for their care and maintenance as well as ethical considerations.  In 
addition, chimpanzees are on the endangered species list which strictly limits 
experimental protocols. 
If barriers to obtaining chimpanzees are overcome, there are endogenous 
limitations that influence the interpretation of results generated in chimpanzees.  
Although humans and chimpanzees share over 98% genome sequence homology (116), 
the differences cannot be underestimated.  Chronic liver disease progression is a 
detrimental effect of HCV infection in humans, yet this is rarely observed in HCV 
infected chimpanzees (117).  Differences in disease progression may be linked to absence 
of common HLA class I alleles and several differences in HLA class II alleles (116).  
These immunological differences also limit the relevance of vaccine studies in 
chimpanzees.  Therefore, chimpanzees pose many limitations and are not an ideal animal 
in which to study HCV infection and pathogenesis. 
 
Humanized mouse models 
 To overcome the limitations of chimpanzees, significant effort to develop a 
humanized mouse model that is susceptible to HCV infection and pathogenesis is 
underway.  Advances in transgenic and knockout mouse models allows for genetic 
deletion of the mouse immune system, enabling transplantation of human tissue without 
immune rejection.  Further, the unique regenerative properties of the liver permit damage 
of the mouse liver and subsequent liver regeneration with transplanted human 
hepatocytes.  Recently, several different types of humanized mouse models have been 
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created on an immunodeficient genetic background expressing toxic genes to induce liver 
damage.  These models consist of either human hepatocytes transplanted into the mouse 
liver or development of a human immune system in mice, but no current model contains 
both.   
 
Alb-uPA mice 
Mouse models with a humanized liver take advantage of the efficient regenerative 
capability of the liver.  When the toxic urokinase plasminogen activator (uPA) gene is 
expressed from the liver-specific albumin enhancer/promoter in transgenic mice (Alb-
uPA), the result is severe hepatotoxicity and often neonatal death.  However, due to DNA 
rearrangement within some hepatocytes, the transgene is abolished and the non-
transgenic cells are able to repopulate the liver (118).    
This discovery led to other groups crossing the Alb-uPA mice with various 
immunodeficient mice, with the goal of repopulating the mouse liver with human 
hepatocytes without immune rejection.  Alb-uPA mice were bred onto the recombination 
activation gene 2 (RAG2) knockout (KO) background, which lacks mature T and B 
lymphocytes, allowing repopulation of woodchuck hepatocytes in the mouse liver and 
infection with  woodchuck hepatitis B virus (119).   
Another group crossed the Alb-uPA mice with immunodeficient SCID mice.  
These mice can also be repopulated with adult human hepatocytes and subsequently 
infected with HCV (120-124).  Although these results seem promising, the Alb-uPA 
immunodeficient mice are not healthy due to the expression of the toxic uPA gene in 
their liver, even with transplanted hepatocytes.  Additionally, nearly 50% of these mice 
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die as newborns, making mouse colony maintenance difficult.  These difficulties 
underscore the need for an inducible method to inflict the liver damage that will allow for 
repopulation with human hepatocytes.  Further limiting the relevance of Alb-uPA mice is 
the lack of a human immune system in which to study HCV immune responses and 
immunopathogenesis. 
 
FRG mice 
Progress towards an inducible liver damage model has been made recently. 
Fumarylacetoacetate hydrolase (Fah) -/- Rag2 -/- γc -/- (DKO) triple mutant mice (FRG) 
can be repopulated with human hepatocytes.  This model has no mouse T, B, or NK cells, 
allowing human cell engraftment without immune rejection.  In addition, the FRG mutant 
mice develop liver disease only when the protective drug 2-(2-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is withdrawn from the drinking 
water.  Therefore, the NTBC must be added to the water to avoid hepatotoxicity and 
mouse death in the absence of transplanted cells.   
Adult human hepatocytes can re-populate the liver of FRG mice, although less 
than 50% of transplanted mice maintain the transplanted cells with an average 
reconstitution of only ~20% (125, 126).  Similar to the Alb-uPA model, the usefulness of 
FRG mice is limited by the lack of a human immune system that would allow for the 
study of viral immunopathogenesis, vaccines, and immunotherapies to treat viral 
infections. 
 
DKO-hu HSC mice 
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Mouse models lacking a human immune system limit the relevance and spectrum 
of results that can be applied towards treating viral infections.  Recently, a humanized 
mouse model containing a human immune system has been established.  The 
immunodeficient DKO mouse develops a functional human immune system upon 
transplantation with human (hu) CD34+ hematopoietic progenitor/stem cells (HSC) to 
generate DKO-hu HSC mice (127, 128).  This mouse model can be efficiently infected 
with HIV-1, causing depletion of human CD4+ T cells and establishment of a persistent 
infection in lymphoid tissues for at least 19 weeks (129).  Additionally, specific immune 
responses to viral infections can be generated in these mice (127).  However, the DKO-hu 
HSC mouse model does not include humanization of the liver.  Since hepatocyte 
progenitor cells, which can be isolated from the same fetal liver as the HSC and 
differentiate into functional hepatocytes (130), they can be transplanted into DKO mice 
along with HSC with no immune rejection.  If the techniques used to generate these 
DKO-hu HSC mice with a human immune system can be used in a model with inducible 
liver damage, a superior humanized mouse model could be created with both a human 
immune system and liver.  This proposed model would not only allow for study of 
immunopathogenesis of HBV and HCV, but also the interaction and disease progression 
of these viruses with HIV. 
 
Scope of this dissertation 
This dissertation encompasses the role of LIGHT as an immunotherapy to clear 
persistently expressed foreign antigens from AAV vectors in the liver, as well as the 
development of a novel humanized mouse model that is susceptible to HCV infection and 
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immunopathogenesis.  In the second chapter, I utilize AAV to model a persistent foreign 
antigen expression in the liver that is not cleared by the immune system.  To test the 
capacity of LIGHT as an immunotherapy, I demonstrate that Ad-LIGHT treatment in 
mice with established AAV vector expression led to clearance of the AAV, correlating 
with enhanced CD8 effector T cells in the liver and inflammation.  Next, knockout mice 
for the receptors of LIGHT were utilized to determine the mechanism of viral clearance.  
While Ad-LIGHT cleared AAV in wild type and both LTβR-null and HVEM-null mice, 
no significant liver inflammation was observed in LTβR-null.  In the third chapter, I 
discuss the development of an improved humanized mouse model designed to study 
human hepatotropic viruses and their interaction with both the human immune system 
and liver.  I demonstrate that AFC8/DKO-hu HSC/Hep humanized mice are susceptible 
to HCV infection, mount a human immune response to HCV, and develop liver fibrosis.  
In the final chapter, I discuss the implications of these findings and the future directions 
of these studies. 
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Abstract 
 
Infection with adeno-associated virus vectors (AAV) with liver tropism leads to 
persistent expression of foreign antigens in the mouse liver, with no significant liver 
inflammation or pathology.  We showed that expressing LIGHT with an adenovirus 
vector (Ad) in mice with established AAV in the liver led to clearance of the AAV.  Ad-
LIGHT enhanced CD8 effector T cells in the liver, correlated with liver inflammation.  
LTβR-Ig proteins blocked Ad-LIGHT in clearing AAV.  Interestingly, Ad-LIGHT 
cleared AAV but caused no significant liver inflammation in LTβR-null mice, whereas 
Ad-LIGHT both cleared AAV and induced liver injury in HVEM-null mice.  Our data 
suggest that LIGHT interaction with LTβR plays a critical role in liver inflammation but 
is not required for LIGHT-mediated AAV clearance. These findings will shed light on 
developing novel immuno-therapeutics in treating people chronically infected with 
hepato-tropic viruses. 
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Introduction  
 
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection leads to 
liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) (1).  Similar to HBV 
and HCV, adeno-associated virus vectors (AAV) are able to establish persistent foreign 
antigen expression in the liver (2).  The mechanism of these viruses to evade host T cell 
responses and persist in the liver is not clear.  AAV vectors can impair T cells specific for 
the transgene (3) (4). The functional impairment of CD8 T cells contributes to persistent 
foreign antigen expression from AAV vectors, as is observed in HBV and HCV infection 
in humans.  
LIGHT (homologous to Lymphotoxins, exhibits Inducible expression, and 
competes with HSV Glycoprotein D for Herpesvirus entry mediator (HVEM), a receptor 
expressed by T lymphocytes) is a member of the TNF superfamily (TNFSF14) that 
interacts with the LTβR (5, 6) and HVEM (7, 8) receptors.  LIGHT has been reported to 
stimulate T cell responses.  Ectopic expression of LIGHT in the tumor induces a massive 
infiltration of T cells, correlated with expression of chemokines, adhesion molecules, and 
rejection of established tumors at local and distal sites (9).  Additionally, injection of an 
adenoviral vector expressing LIGHT (Ad-LIGHT) into tumor tissue leads to generation 
of tumor-specific CTL and rejection of both established and disseminated metastasizing 
tumor cells in the peripheral tissues of mice (10).  Stimulation of the HVEM pathway 
with LIGHT enhances co-stimulation of T cell activation (11). By blocking the 
interaction of LIGHT with the LTβR or HVEM receptors, using a soluble HVEM-Fc or 
LTβR-Fc fusion protein, the allogenic T cell responses and host-specific CTL responses 
are significantly reduced (12, 13).  
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In the liver, LTβR is expressed on Kupffer cells and may be involved in the 
process of T cell tolerance induction (14).  Additionally, the LTβR is also expressed on 
hepatocytes, where it contributes to liver regeneration and liver homeostasis (15).  In 
transgenic mice expressing LTα-β, blocking LTβR signaling reduced inflammation in the 
liver (16).  It is reported that the HCV core protein directly interacts with LTβR, which 
may contribute to HCV-induced liver diseases (17).  Since the LIGHT/LTβR-HVEM 
signaling pathway is involved in modulation of immune responses in the liver, we 
investigated their function in the liver to test whether we can induce immune activation to 
clear the AAV in the liver using adenovirus-mediated LIGHT expression in the liver. 
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Materials and Methods 
 
Mice.  
Male C57BL/6 mice (6 to 8 weeks old) were purchased from the Jackson 
Laboratory (Bar Harbor, ME), HVEM-null and LTβR-null mice were maintained at the 
DLAM facility at the University of North Carolina at Chapel Hill and the University of 
Chicago.  Procedures for the animal work were approved.  
 
AAV and adenovirus viral vectors and mouse inoculations.  
AAV vectors expressing eGFP under the control of the U1a promoter were 
generated by the UNC Vector Core Facility.  A self-complementary adeno-associated 
virus vector serotype 8 (AAV) was kindly provided by Dr. R. Jude Samulski (Chapel 
Hill, NC) and used for the construction of the eGFP construct.  The recombinant Ad5 
(E1/E3-) adenoviral vector expressing β-galactosidase (Ad-Ctrl) and Ad-LIGHT was 
generated as described (10).  To inoculate mice, 1x1011 vp AAV were injected through 
the portal vein.  For Ad vector injection, 3x1010 vp Ad- vectors were injected 
intravenously 2-3 weeks after AAV inoculation. 
 
Antibodies.  
CD4-Pacific Orange, CD44-FITC, VLD, IFNγ-FITC (Invitrogen), CD8-PE Texas 
Red (Southern Biotech), and IL-2 –PE (BD Pharmingen) were purchased.  The JL-8 GFP 
antibody was from Clontech. Anti-CD3 mAB (BD Pharmingen) was used to stimulate T 
cells. LTβR-Ig was produced as described previously (18, 19).  Human control IgG was 
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obtained from Biogen Inc.  LTβR-Ig or Human IgG (200ug/kg) was injected i.p. weekly 
for three weeks, once right before and twice after adenovirus injection in AAV infected 
mice.  
 
PCR, Western blotting, ALT, and liver histopathology.  
Mice were bled and serum was isolated to measure ALT levels.  DNA was 
isolated from ~10mg of liver tissue using a Qiagen DNeasy kit. PCR primers were 
designed for a 150bp fragment of eGFP and p18 primers were used as a loading control. 
25ng of DNA was used in a PCR reaction.  Protein was isolated from the liver and 100ug 
of protein was used for a Western blot to detect eGFP or tubulin.  Liver sections were 
fixed in 10% formalin and paraffin sections were stained by H&E for the detection of 
leukocyte infiltration. 
 
Cell isolation, stimulation and flow cytometry.  
Liver leukocytes were isolated essentially as described (20).  Briefly, the liver 
tissue suspension was prepared, passed through a 70um nylon cell strainer and treated 
with ACK lysis buffer to remove red blood cells.  The cells were washed in IMDM/10% 
FBS + 0.002% DNase, then re-suspended in 40% Percoll (SIGMA) containing 
IMDM/10% FBS, loaded onto a 70% Percoll layer, and centrifuged for 20 minutes at 
3000 rpm.  Cells were counted using the Guava automated cell counter.  The cells were 
stained with antibodies for CD4, CD8 and CD44.  For T cell activation, 1x105 cells were 
stimulated with 5ug/ml anti-CD3 mAb for 18h, then harvested and stained for CD4, CD8 
and intracellular cytokine expression of IFN-γ and IL-2.  Flow cytometry was performed 
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on a CyAn FACS machine (Dako North America, Carpinteria, CA) and analyzed with 
Summit software. 
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Results and Discussion 
 
Ad-LIGHT causes clearance of AAV genomes in the liver.   
We used self-complementary adeno-associated virus (AAV) vectors packaged 
with serotype 8 (21), which is liver tropic in vivo.  The U1a promoter was used to drive 
the expression of GFP in transduced hepatocytes (22).  We demonstrated that AAV-GFP 
infection with persistent GFP expression in the liver was efficiently established for at 
least 86 days (Fig. 2.1A and Fig. 2.2A,B), and by with no increase in ALT throughout the 
infection (Fig. 2.1B). Therefore, AAV-U1a-GFP established a long term persistent 
expression of GFP in the liver with no significant liver inflammation.  
The LIGHT/LTβR-HVEM signaling pathway in the liver is involved in 
modulation of immune responses and liver growth regulation; and LIGHT is a potent co-
stimulator of T cells.  We postulate that the T cell tolerance induced by hepatic infection 
of AAV-GFP may be reversed by LIGHT treatment.  To test this hypothesis, we 
investigated the functions of this pathway in the liver to determine whether we can induce 
immune activation to clear the AAV in the liver using adenovirus-mediated LIGHT 
expression in the liver.  We used the replication-deficient adenovirus vector to express 
LIGHT (Ad-LIGHT) in vivo (10).  First, we infected C57/BL6 mice with AAV-GFP 
through the portal vein.  After 18-21 days, mice were injected with Ad-LIGHT, Ad-Ctrl 
vector, or PBS.  At 3-8 weeks after adenovirus injection, GFP expression and AAV 
genome levels in the liver were determined.  AAV-GFP expressing mice treated with Ad-
LIGHT, but not with Ad-Ctrl vector, diminished GFP expression in the liver (Fig. 2.2C).  
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Figure 2.1. AAV infection causes a persistent transgene expression in mouse 
hepatocytes.  C57BL/6 mice were injected with PBS or 1x1011 vp AAV-GFP and 
sacrificed two to nine weeks p.i. (A) Representative liver sections from an uninfected 
mock and AAV-GFP infected mouse. The top panel is GFP expression in liver tissue and 
bottom is panel are liver sections stained with H&E showing no leukocyte infiltration.  
(B) Peripheral blood was drawn from the mice throughout the course of infection. ALT 
levels were measured in the serum of both groups of mice with no difference observed at 
any time point.  
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Figure 2.2. Ad-LIGHT induces clearance of AAV in the liver. C57BL/6 mice were 
injected with PBS or AAV-GFP vector. (A) Protein was isolated from the livers at 18 to 
86 dpi. GFP protein was detected by Western blot with tubulin as a control. (B) Primers 
for GFP (AAV) were used to measure AAV genomes in the liver DNA, with p18 
(control) as a host DNA control. AAV-GFP plasmid DNA was used as a positive control. 
H2O indicates no template DNA control. (C-E) Mice infected with AAV for 2-3 weeks 
were infected with either Ad-LIGHT or Ad-Ctrl (Control) vector. Mice were sacrificed 
~4 weeks post adenovirus injection and protein or DNA was isolated from the liver. (C) 
Western blot analysis for GFP and tubulin in the liver of two mice from a representative 
experiment is shown. Mock or AAV-GFP only samples were included as controls. (D) 
DNA was used to detect AAV genomes in the liver after Ad-Ctrl (two mice) or Ad-
LIGHT (3 mice) treatment. (E) Mice infected with AAV were treated with LTβR-Ig or 
control IgG and infected with Ad-LIGHT or Ad-Ctrl DNA was isolated from the liver 
and used to detect AAV genomes.  AAV-infected mice with Ad-Ctrl only were used as 
controls. Data are representative of 4 independent experiments with 2-4 mice per group in 
each experiment. 
 44 
Similar results were obtained by PCR to determine the AAV genomes in the liver (Fig. 
2.2D).  When the LTβR-Ig fusion protein was added to the treated mice, it blocked the 
ability of Ad-LIGHT to clear AAV (Fig. 2.2E).  These data indicate that ectopic 
expression of LIGHT via adenoviral vectors in the liver can lead to clearance of AAV via 
interaction with its receptors.    
 
LIGHT-mediated clearance of AAV correlates with increased liver inflammation 
and CD8+ effector T cells in the liver.  
In LIGHT-treated mice, a significant level of liver injury was detected by ALT or 
intra-liver infiltration (Fig. 2.3).  ALT levels were measured at various time points post 
adenovirus injection.  Ad-Ctrl infected mice induced low levels of ALT.  However, Ad-
LIGHT infected mice induced a higher ALT level than Ad-Ctrl mice (Fig. 2.3A).  This is 
confirmed by an increase in the number of leukocytes present in the liver as seen by H&E 
sections (Fig. 2.3B) and by the total number of intra-hepatic leukocytes (Fig. 2.3C).  The 
ALT level returned to normal around 60 dpi in both Ad-LIGHT and Ad-Ctrl infected 
mice (data not shown). 
To determine the immune effector cells that were stimulated by LIGHT, 
leukocytes were isolated from the liver and the spleen for analysis.  We observed no 
increase in the percentage of CD4+CD44+ T cells in the liver (data not shown).  In 
contrast, there was a significant increase in the percentage of CD8+CD44+ T cells in both 
the liver and spleen of mice injected with Ad-LIGHT when compared to Ad-Ctrl (Fig. 
2.4A-D).  
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Figure 2.3. Ad-LIGHT induces liver inflammation. C57BL/6 mice were injected with 
PBS or AAV-GFP, and after 2-3 weeks injected with Ad-Ctrl or Ad-LIGHT.  (A) Blood 
was drawn from the mice at 15 and 28 days post Adenovirus injection, and ALT was 
measured. Error bars indicate standard deviations. (B) Liver sections were stained with 
H&E to visualize leukocyte infiltration. (C) Liver leukocytes were isolated from the mice 
and counted. Data are representative of 4 independent experiments with 3-4 mice per 
group in each experiment. **, p<0.01. 
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To further characterize the immune response, we stimulated splenocytes or liver 
leukocytes with anti-CD3.  Interestingly, there was a significant increase in the 
percentage of IFN-γ+ CD8+ in both the liver (Fig. 2.4E,F) and spleen (data not shown). 
LIGHT did not enhance IFN-γ expression in CD4+ cells either from the liver or spleen 
(data not shown).  This result is consistent with reports that LIGHT is a co-stimulator of 
CD8+ T cells and causes an increase in IFN-γ production (11, 23), and that OT-I CD8 T 
cells, when transferred into mice with persistent Ova expression from an AAV vector, 
express IFN-γ and induce liver injury via activation of Kupffer cells (20).  
 
LTβR is not required for AAV clearance but is critical for LIGHT-induced liver 
inflammation. 
 To determine if LTβR or HVEM is required for LIGHT mediated clearance of 
AAV and liver injury, we tested the effect of Ad-LIGHT in LTβR-null and HVEM-null 
mutant mice (Fig. 2.5).  Interestingly, Ad-LIGHT led to clearance of AAV in wild type 
and both mutant mice, suggesting that neither LTβR nor HVEM alone was critically 
required for LIGHT-mediated AAV clearance (Fig. 2.5A).  It is likely that they are 
redundantly involved in mediating LIGHT induced AAV clearance.  We also examined 
the liver for inflammation and leukocyte infiltration.  Ad-LIGHT infected wild type or 
HVEM-null mice showed a higher ALT level and lymphocyte infiltration than control 
mice (Fig. 2.B-D).  However, we observed only a low ALT induction and no significant 
leukocyte infiltration into the liver of LTβR-null mice treated with Ad-LIGHT (Fig. 
2.5B-D).  We conclude that the LTβR is required for LIGHT-mediated liver 
inflammation and injury, but not for its AAV clearance activity.  
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Figure 2.4. LIGHT-mediated clearance of AAV correlates with increased CD8+ 
activated and effector T cells in the liver. C57BL/6 mice previously inoculated with 
AAV-GFP were injected with Ad-Ctrl or Ad-LIGHT vector for 3-5 weeks. Leukocytes 
were isolated from the (A,B) liver and (C,D) spleen and stained with surface markers and 
analyzed for CD8 and CD44 expression. * P < 0.05  
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Figure 2.4, continued. Alternatively, the (E,F) liver cells were stimulated with anti-CD3 
(5ug/mL) for 18h. The cells were then stained for surface markers and intracellular IFNγ. 
A representative FACS plot is shown for each group. Numbers are % IFNγ+ of CD8 T 
cells. Summarized data are shown from 3 independent experiments with 3-4 mice per 
group per experiment. * P < 0.05. 
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Figure 2.5. Ad-LIGHT clears AAV in LTβR -/- with no liver injury. (A) Wild type or 
LTβR-null mice infected with AAV-GFP were injected with Ad-Ctrl or Ad-LIGHT. 
DNA from the liver was used to detect AAV genomes. Lanes 1&2 = AAV-GFP + Ad-
LIGHT (LTβR -/-), 3&4 = AAV-GFP + Ad-Ctrl (LTβR -/-), 5&6 = AAV-GFP + Ad-
LIGHT (WT), 7&8 = AAV-GFP + Ad-Ctrl (WT), lane 9 = water control. (B) Wild type 
or HVEM-null mice infected with AAV-GFP were injected with Ad-Ctrl or Ad-LIGHT. 
DNA from the liver was used to detect AAV genomes. Lanes 1&2 = AAV-GFP + Ad-
LIGHT (HVEM -/-), 3&4 = AAV-GFP + Ad-Ctrl (HVEM -/-), 5&6 = AAV-GFP + Ad-
LIGHT (WT), 7&8 = AAV-GFP + Ad-Ctrl (WT), lane 9 = water control. (C) The livers 
of mice in all groups were weighted upon sacrifice, with an increase in liver mass in wild 
type and HVEM-/- but not LTβR-/- mice treated with Ad-LIGHT. (D) Serum ALT was 
measured 21 days after Ad-LIGHT or Ad-Ctrl injection. * P < 0.05 when compared to 
Ad-Ctrl treatment. (E) Wild Type (WT), HVEM -/- and LTβR -/- mice treated with AAV 
+ Ad-LIGHT were sacrificed 3-4 weeks post adenovirus injection and liver sections 
stained with H&E. The data are representative of 2 experiments with 3 mice per group 
per experiment. 
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In summary, delivery of Ad-LIGHT in mice with a persistent AAV infection led 
to clearance of AAV from the liver, correlated with elevated CD8+ effector T cells and 
liver injury.  The LIGHT receptor HVEM was not required for either AAV clearance or 
liver injury.  However, the LTβR was required for LIGHT-induced liver inflammation 
but not for LIGHT-mediated AAV clearance.  Therefore, LIGHT mediates distinct 
signals to clear AAV vectors in the liver and to induce liver inflammation.  These 
findings may help to develop novel immunotherapeutic strategy to clear persistent viral 
infections in the liver. 
The interaction of LIGHT-HVEM induces co-stimulation of CD8+ T cell 
activation, production of IFN-γ, and modulation of T cell responses (11, 23).  Since we 
observed a significant increase in effector CD8+ T cells and IFN-γ in LIGHT treated 
mice, the interaction of LIGHT with HVEM likely contributes to clearance of the AAV 
in the liver.  However, our experiments with HVEM-null mice showed that it was not 
required for the LIGHT mediated clearance of AAV from the liver.  It is likely that 
HVEM and LTβR are redundantly involved in mediating LIGHT induced AAV 
clearance.  Alternatively, a third unidentified LIGHT receptor may be involved.  Our 
preliminary results showed that LIGHT can efficiently stimulate HVEM-null T cells.  As 
LTβR is not expressed on T cells, our results suggest the presence of a novel LIGHT 
receptor on T cells (YX Fu, unpublished results).  The LIGHT-LTβR interaction has been 
shown to induce apoptosis (24), produce cytokines involved in development of lymph 
nodes (25), and restore secondary lymphoid structure and function (26).  Our data suggest 
that it is feasible to generate mutant LIGHT molecules that specifically lose interaction 
with LTβR as novel therapeutics that can clear liver-tropic virus without liver injury. 
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Chapter III 
 
 
A novel humanized mouse model with a human immune system and human 
liver supports HCV infection, immune responses, and pathogenesis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been adapted from: Michael L. Washburn, Moses T. Bility, Grigoriy I. 
Kovalev, Liguo Zhang, Qi Jiang, Alexander Ploss, Jeffery Frelinger, Charles M. Rice, 
and Lishan Su.  Modeling HCV infection, immune responses, and pathogenesis in a novel 
mouse model with both a human immune system and liver. 2010. Manuscript in 
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Abstract  
 
 
Studying HCV infection, immunopathogenesis, and associated liver diseases is 
hampered by the lack of a robust model.  Rag2-/- γc-/- (DKO) mice lack T, B, and NK cells and 
can be engrafted with a functional human immune system.  To engraft human hepatocytes, we 
created a transgenic mouse with the FKBP-caspase 8 fusion gene under control of the 
albumin enhancer/promoter (AFC8/DKO).  Transplanting AFC8/DKO mice with human 
HSC and hepatocyte progenitors, upon induction of mouse hepatocyte apoptosis, lead to 
efficient engraftment of human hepatocytes and leukocytes (AFC8/DKO-hu HSC/Hep 
mice).  AFC8/DKO-hu HSC/Hep mice supported long-term HCV infection in the liver 
and induced human immune responses to HCV.  In addition, HCV infection induced liver 
inflammation and fibrosis, correlated with activation of stellate cells and expression of 
human fibrogenic genes.  The AFC8/DKO-hu HSC/Hep mouse will greatly advance the 
study of HCV infection, immunopathogenesis, and development of improved therapies to 
combat infection and liver disease progression.  
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Introduction  
 
The liver is the primary site for hepatitis B (HBV) and hepatitis C virus (HCV) 
infection.  Over 500 million people worldwide are chronically infected by these viruses, 
often resulting in fibrosis/cirrhosis of the liver and development of hepatocellular 
carcinoma (HCC) (1).  With nearly 80% of HCC caused by HBV and HCV infection (1), 
the global health threat of these viruses cannot be underestimated.   Infection is often 
associated with impaired T cell responses to viral antigens and chronic inflammation in 
the liver, leading to activation of hepatic stellate cells and progressive liver disease (2-4).  
There is no effective therapy to eliminate these viruses, largely due to lack of an 
appropriate model system to study all aspects of the virus life cycle and subsequent 
disease progression.  Since the immune system plays a critical role in HBV and HCV 
infection and disease progression, a model system that incorporates both a human liver 
and immune system is urgently needed.   
Although chimpanzees can be infected with HBV and HCV, and have provided 
insights into immunity and disease progression (5), there are several drawbacks which 
limit their usefulness.  The availability of chimpanzees for research is severely limited, in 
part due to the significant costs for their care and maintenance as well as ethical 
considerations.  In addition, chimpanzees are on the endangered species list which strictly 
limits experimental protocols.  Notably, chronic liver disease progression is a detrimental 
effect of HCV infection in humans, yet this is rarely observed in HCV infected 
chimpanzees (6).  To overcome the limitations of chimpanzees, significant effort to 
develop a humanized mouse model that is susceptible to HBV, HCV infection and 
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pathogenesis is underway.  Recently, several different types of humanized mouse models 
have been created on an immunodeficient genetic background expressing cytotoxic genes 
to induce liver damage.  Both the Alb-uPA and FRG mouse models allow for 
repopulation of human hepatocytes in the mouse liver (7-15).  However, these mice have 
several disadvantages, highlighted by lack of a human immune system.  
To overcome the pitfalls, we generated a transgenic immunodeficient mouse 
expressing an inducible suicidal FKBP-caspase 8 gene in the liver, which has been used 
successfully to delete adipocytes in vivo (16).  This system allows for inducible 
dimerization and activation of a protein of interest, which is induced by an FK1012 
analog, AP20187.  The affinity of AP20187 to interaction with FKBPv  is over a 
thousand fold greater than the endogenous FKBP (17), which highlights the tight 
regulation of this system.   
Capases are integral components of the apoptotic response.  They initiate an 
irreversible commitment for a cell to die and are a conserved throughout many species 
(18, 19).  Caspase 8 is an initiator caspase that is responsible for cleavage and activation 
of the effector caspase 3 (20).  Activation of caspase 3 results in apoptosis of the target 
cell.  We are utilizing this natural mechanism of cell death in to create an improved 
humanized mouse model, as opposed to the toxic injury caused in other models.   
It has been reported that a functional human immune system can develop in 
humanized Rag2 -/- γc-/- (DKO-hu HSC) mice (21-23).  We created a transgenic DKO 
mouse expressing the FKBP-caspase 8 fusion gene under control of the albumin promoter 
(AFC8/DKO).  We co-transplanted human hepatocyte progenitor cells (Hep) and CD34+ 
hematopoietic stem/progenitor cells (HSC) into AFC8/DKO mice and murine 
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hepatocytes were depleted with the FKBP dimerizer.  Human immune cells developed in 
all lymphoid organs including the liver of humanized mice.  In addition, functional 
human hepatocytes were also efficiently developed (AFC8/DKO- hu HSC/Hep), thereby 
generating a mouse model containing both a human immune system and liver. 
AFC8/DKO-hu HSC/Hep mice supported long-term HCV infection in the liver and 
induced human immune responses to HCV.  In addition, HCV infection induced liver 
inflammation and fibrosis, correlated with activation of stellate cells and expression of 
human fibrogenic genes.  The AFC8/DKO-hu HSC/Hep mouse will greatly advance the 
study of HCV infection, immunopathogenesis, and development of improved therapies to 
combat infection and liver disease progression. 
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Materials and Methods 
 
Plasmids 
The transgenic template construct (pTG1) was obtained from the UNC transgenic 
core facility.  It was cut with XbaI and ligated to the Albumin enhancer/promoter from 
the 2335A-1 plasmid (kindly provided by Dr. Snorri Thorgessons, NIH).  The FKBP-
caspase 8 gene was generated by cloning human caspase 8 (fragment Ser217-Asp479) 
cloned into the pC4M-Fv2E vector (Ariad Pharmaceuticals) to express the FKBP-caspase 
8 fusion protein (kindly provided by Dr. Terry Combs, Chapel Hill).  The FKBP2-
caspase 8 fusion gene was ligated into the pTG1-Alb e/p plasmid to create the AFC8 
construct.   Plasmids used as controls in vitro included pCDNA, pMaxGFP or a plasimid 
expressing GFP from the U1a promoter (24). 
 
In vitro induction of apoptosis 
293T and HepG2 cells were transfected using FuGENE6 (Roche) with a plasmid 
expressing eGFP or co-transfected with the AFC8 or CFC8 construct.  Transfected cells 
were cultured for 30 hours in DMEM 10% FBS and titrated doses (0-2nM) of AP20187 
(reconstituted in 4% ethanol, 10% PEG-400, 2% Tween-20 in water) was added to the 
media.  After 24 hours, the cells were harvested, stained with 7AAD, and analyzed for 
GFP expression and cell viability on a Guava automated cell counter (Millipore).  To 
detect caspase 3/7 activity, Promega Caspase 3/7 Glo assay was used following 
manufacture's recommended procedures.  
 
Generation of AFC8/DKO mice 
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 Approval for animal work was obtained from the University of North Carolina 
Institutional Animal Care and Use Committee (IACUC).  BALB/c Rag2 -/- γc -/- double 
knockout (DKO) female mice were super-ovulated and the fertilized eggs were isolated 
by standard procedures in the UNC transgenic core facility.  The AFC8 transgene was 
linearized by NotI digestion, injected into fertilized eggs, and implanted into surrogate 
mother mice.  Screening for the AFC8 transgene was done by PCR, and founder mice 
were confirmed by Southern blot.  AFC8/DKO mice were bred and handled under 
specific pathogen free conditions in the UNC DLAM facility. 
 
Verification of founder mice and caspase 8 expression in different tissues 
DNA was isolated from ear or tail clips from DKO and AFC8/DKO using a 
DNeasy kit (Qiagen).  PCR primers for the human caspase 8 gene were used to identify 
transgenic mice.  Founder mice were verified by Southern blot using genomic DNA from 
DKO or AFC8/DKO mice.  The DNA was run on a 0.8% agarose gel, transferred to a 
nitrocellulose membrane, and a probe that binds to the albumin enhancer/promoter was 
labeled with 32P and used to detect the transgene.  mRNA was isolated from liver, spleen, 
kindey, and heart of AFC8/DKO and DKO mice.  cDNA was generated and quantitative 
real time PCR analysis was performed to determine caspase 8 expression. 
 
Induction of murine hepatocyte depletion in AFC8/DKO mice 
We injected mice IP and IV with AP20187 (Ariad Pharmecuticals) or vehicle only 
(4% ethanol, 10% PEG-400, 2% Tween-20 in water) at a dose of 5ug/g body weight at 
various intervals 0-90 days post transplant of human cells. 
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Liver processing to isolate HSC and Hep cells  
Human hepatocyte progenitor and  CD34+ cells were isolated from 17-20 week 
old human fetal liver tissue essentially as described (25, 26).  Briefly, the tissue is first 
perfused with Liver Perfusion Medium and then with Liver Digest Medium (Invitrogen). 
Subsequently, the digested liver is placed in Hepatocyte Wash Medium (Invitrogen), and 
the cell suspension is filtered through a 70-um cell strainer (BD Falcon).  To separate 
parenchyma hepatocytes from non-parenchymal cells (including HSC) the cells were 
centrifuged at low speed three times (5 minutes, 50xg).  Hepatocytes (including 
hepatoblasts/progenitors) were collected in the pellet.  The supernatant was centrifuged at 
150xg for 5 min to collect the non-parenchyma mononuclear cells.  Cell viability, 
measured using Guava via-count, generally exceeded 90%.  CD34+ cells were isolated by 
magnetic-activated cell sorting (MACS), and the purity of CD34+ HSCs was greater than 
95%.  Adult hepatocyte cell suspensions were obtained from Cellz Direct (Durham, NC).   
 
Transplantation of AFC8/DKO mice 
CD34+ HSCs (0.4 -1x106) together with 0.5-1x106 Hep in DMEM were injected 
into the liver of 1 to 5 day old DKO and AFC8/DKO mice, which had been previously 
irradiated at 400 rad (sublethal). 1x106 adult hepatocytes were administered through 
intra-splenic injection in adult mice.  
 
Blood and tissue analysis 
 At 12-15 weeks post transplant with HSC+Hep, mice were bled to determine 
human leukocyte reconstitution in the blood, which was generally between 10-50%, and 
human albumin concentration.  Mice transplanted with adult hepatocytes were bled 3 
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weeks post transplant.  Serum samples were analyzed for human albumin by ELISA 
(Bethyl laboratories).  The ALT assay was performed with serum from infected and 
uninfected animals using MaxDiscovery Alanine Transaminase (ALT) Color Endpoint 
Assay Kit (Bioo Scientific Corp, Austin, TX) and following manufacturer's 
recommended procedures.  Liver tissue was harvested and fixed in 10% formalin, 
immediately snap frozen for DNA isolation, or placed in RNAlater (Qiagen) to isolate 
RNA.  Paraffin embedded fixed liver sections were stained with antibodies for 
hematoxylin and eosin (H&E), Sirius Red and Fast Green, α smooth muscle actin (1:75; 
Dako), anti-human CD45 (1:2, Dako), anti-human albumin (1:250; Dako).  
Immunoreactivity was determined by incubation with DAB substrate (Pierce) or Vulcan 
red (Dako), then counterstained with hematoxilin.  
 
HCV infection 
 AFC8/DKO-hu HSC/Hep mice were inoculated IV with 100ul of clinical isolates 
of HCV genotype 1 (~5x106 IU/ml) or control human sera. 
 
Quantitative real time PCR analysis 
Liver tissue was harvested and placed in RNAlater (Qiagen).  mRNA was isolated 
from liver samples using an RNeasy kit (Qiagen).   cDNA was generated by an RT PCR 
kit (Invitrogen).  Human specific quantitative real time PCR primers were designed using 
NCBI primer design program and database, which include; human albumin, UGT2B7, 
Cyp2E9, Cyp2E1, TIMP1, COL1A1, and both human and murine GAPDH.  Gene 
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expression analysis was examined using Thermo Scientific SYBR Green Realtime PCR 
reagents.  Values shown are relative gene expression normalized to GAPDH. 
 
T cell activation and FACS analysis  
Liver leukocytes were isolated from AFC8/DKO-hu HSC/Hep mice and analyzed 
by FACS for human surface markers; CD45, CD3, CD4, CD123, CD16, CD56 (BD) and 
CD8, CD25, LD7, mCD45 (Invitrogen).  Splenocytes and mesenteric lymph nodes were 
isolated from individual mock and HCV infected AFC8/DKO-hu HSC/Hep mice, mixed, 
then 50,000 – 100,000 cells human (h) CD45+ cells were stimulated for 20 hours with 
10ug/ml PHA in IMDM + 10% FBS media (Gibco).  The cells were then harvested, 
FACS stained for surface markers (hCD45, CD3, CD4, CD8, LD7, mouse CD45), then 
intracellular stained for human IL-2, TNF-α (Biolegend), and IFN-γ (BD).  Cell 
populations were analyzed by first gating on live (LD7-), mouse CD45-, hCD45+, 
hCD3+, then further gated on by the indicated populations.  Human T cells were 
expanded by stimulating 5x105 – 1x106 spleen/mLN cells with a pool of 19 HCV core 
peptides (20mer overlapping by 10) at 10ug/ml each + 1ug/ml anti-CD28 mAb.  The 
peptides were reconstituted in sterile distilled water containing 10% dimethyl sulfoxide 
(DMSO).  The cells were then cultured for 7 days with half fresh media (IMDM, 10% 
FBS) being replaced every two days, containing human IL-2 (10U/mL) and IL-7 
(125ng/mL).   On Day 8, the cells were re-stimulated with the same HCV core peptide 
pool for 18 hours for either Elispot detection of human IFN-γ following the 
recommended protocol (BD), or FACS stained with the same antibodies and procedure 
described earlier.   
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Statistical analysis 
 We performed analysis to determine statistical significance using the Students 
unpaired t test.  All data are reported as means ± standard deviation (s.d.) or standard 
error (s.e.m) as indicated.   
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Results 
 
Hepatocyte death/liver damage can be repeatedly induced in AFC8/DKO mice 
 
We reasoned that specific depletion of murine hepatocytes in the humanized 
chimeric liver will enhance human hepatocyte engraftment.  We have generated an 
FKBP-caspase 8 fusion gene with inducible suicidal activity in cells in which it is 
expressed, but not in bystander cells (Fig. 3.1).  To selectively induce liver cell apoptosis, 
we generated a construct containing the p20 and p10 catalytic domains of human caspase 
8 fused to two modified domains of FKBP, as well as a myristoylation site to target 
expression to the cell membrane (16) (Fig. 3.1A).  The mouse albumin enhancer and 
promoter drives liver specific expression (27, 28).  Dimerization of caspase 8 by 
AP20187 induces apoptosis of cells in which it is expressed (Fig. 3.1B), allowing for 
targeted, inducible apoptosis of a specific cell population.   
We first tested in vitro the function of the albumin-FKBP-caspase 8 construct 
(AFC8), and the same construct driven by the CMV promoter (CFC8).  Transfected 293T 
and HepG2 cells were treated with various doses of the AP20187 dimerizer.  After 24 
hours, the transfected GFP+ or untransfected GFP- cells were analyzed.  In control cells, 
we did not observe cell death upon addition of AP20187 (Fig. 3.2A,C).  In contrast, we 
observed a dose-dependent killing of GFP+ 293T and HepG2 cells transfected with the 
CFC8 construct (Fig. 3.2A,C).  Confirming the tissue specific expression of the albumin 
enhancer/promoter, we observed dose dependent killing of only HepG2 cells, not 293T 
cells, expressing the AFC8 construct (Fig. 3.2C).  Importantly, we did not observe 
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bystander cell death of GFP negative cells (Fig. 3.2B), which underscores the tight 
regulation of this system and provides evidence that it can be used in vivo for specific cell 
depletion without the concern of bystander cell killing.  We next confirmed that the 
mechanism of cell death was through apoptosis by measuring the activity of caspase 3/7 
in the treated cells (Fig. 3.2D).  These data indicates that the activation of caspase 8 is 
tightly regulated by the dimerizer drug AP20187 to cause inducible killing of only 
targeted cells. 
To allow for transplant of human hepatocytes and hematopoietic stem cells 
without immune rejection, we utilized Rag2 -/- γc -/- double knockout mice (DKO).  These 
mice lack T, B, NK cells, allowing for transplantation of foreign cells without immune 
rejection.  We generated transgenic mice with the AFC8 construct on the DKO mouse 
background (AFC8/DKO).  Transgenic founder mice were detected by PCR and Southern 
blot (Fig. 3.3A,C), and quantitative real time PCR confirmed the expression of the AFC8 
transgene to be specific to the liver (Fig. 3.3B).  We determined there to be ~14 copies of 
the transgene in the mice by Southern blot (Fig. 3.3C). 
To induce liver damage in AFC8/DKO mice, we treated both DKO and 
AFC8/DKO mice with AP20187 or vehicle only.  We observed a significant increase of 
ALT in AFC8/DKO mice treated with AP20187, compared to DKO with drug and 
AFC8/DKO mice with vehicle (Fig. 3.1C).  Upon injection of another dose of AP20187, 
the ALT levels increased again in AFC8/DKO, but remained at baseline levels in control 
mice (Fig. 3.1C).  We observed numerous pockets of degenerating liver cells throughout 
the liver in AFC8/DKO mice treated with drug, whereas the liver of control mice was  
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Figure 3.1. Hepatocyte death/Liver damage can be repeatedly induced in 
AFC8/DKO mice. (A) The structure of the transgenic construct.  Expression of the 
Caspase 8-FKBP fusion gene is driven by the liver-specific albumin enhancer/promoter.  
(B) Inducible activation of Caspase 8 through dimerization. The chemical dimerizer 
AP20187 causes dimerization/activation of Caspase 8 through interaction of adjacent 
FKBP binding sites. M, myristoyation signal; FKBP, FK506 analog binding domain; 
Caspase 8, human Caspase 8 (fragment Ser217-Asp479).  (C) Repeated, inducible liver 
damage in AFC8/DKO mice.  AFC8/DKO and DKO mice were injected with 5ug/g body 
weight AP20187 IV, or left untreated. Serum was isolated from the mice pre, 24h, and 
72h post-drug and ALT was measured.   Data are representative of three experiments 
with n = 4 per group. Data represent means ± s.d. * P < 0.05 (D) Liver damage of  
AFC8/DKO mice.  Representative liver sections (20x and 40x) stained with H&E from a 
DKO and AFC8/DKO liver 24h after injection of 5ug/g AP20187. V, vein; arrow heads 
point to pockets of liver degeneration. (E) No damage in other organs.  Representative 
heart, spleen, and kidney sections (10x) stained with H&E from DKO and AFC8/DKO 
mice 24h after injection of 5ug/g AP20187. 
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Figure 3.2. FC8 activation leads to death of target cells in vitro. The FKBP-Caspase 8 
gene driven by the CMV promoter (CFC8) or albumin promoter (AFC8) was co-
transfected with a GFP-expressing plasmid into (A) HepG2 liver cells and (C) 293T cells.  
Transfected cells were cultured for 30 hours and titrated doses of the AP20187 dimerizer 
was added to the culture media. The cells were cultured for 24h, harvested, stained with 
7AAD, and analyzed by FACS for GFP expression and 7AAD.  Inducible, hepatocyte 
specific apoptosis was observed (A,C) with the AFC8 construct with (B) no bystander 
cell killing.  (D) Effector Caspase 3/7 downstream of caspase 8 were induced with 
titrated doses of AP20187, indicating apoptosis as the mechanism of cell death. 
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Figure 3.3. Detection of the transgene and expression of FKBP-Caspase 8 in the 
liver of AFC8/DKO mice.  Standard transgenic mouse procedure was used to inject the 
transgene construct into fertilized DKO embryos.  (A) The transgenic founder mice were 
identified by PCR.  The PCR was run using primers to amplify the FKBP-Caspase 8 
region of the transgenic construct or the endogenous p18 gene in mice for a control.  
300fg transgenic plasmid DNA,100ng of mouse genomic DNA, a mixture of 300fg 
plasmid + 100ng mouse genomic DNA, water + PCR mixture, and DNA from a 
transgenic founder mouse are shown.  (B) To demonstrate liver specific expression of 
caspase 8, RNA was isolated from the liver, spleen, heart, and kidneys of AFC8/DKO 
mice.  cDNA was generated from the RNA and used as a template.  SYBR green real 
time PCR specific to human caspase 8 demonstrated expression of caspase 8 only in the 
liver of AFC8/DKO mice.  Control cDNA samples were made without using reverse 
transcriptase (-RT).  Data represent mean ± s.d. * P < 0.05 (C) AFC8/DKO founder 
mouse was verified by Southern blot. A probe from the endogenous albumin 
enhancer/promoter region was labeled with 32P and incubated with 2 and 5ug of genomic 
DNA from AFC8/DKO and 5ug from DKO mice. The endogenous albumin 
enhancer/promoter is separated by ~3kb, but fused together in the AFC8 construct 
allowing for an internal reference of 2 gene copies.  The bands were quantitated by a 
phosphoimager to determine there are ~14 copies of the transgene in the AFC8/DKO 
founder mouse. 
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normal (Fig. 3.1D) and all other organs analyzed in treated DKO and AFC8/DKO mice 
appeared normal (Fig. 3.1E).     
 
AFC8/DKO-hu HSC/Hep mice can be efficiently repopulated with a human liver 
and immune system 
To test the ability of the AFC8/DKO mice to engraft human hepatocytes, we first 
transplanted them and DKO mice with human adult hepatocytes by intra-splenic 
injection.  Transplant was followed with injections of AP20187 to induce depletion of 
murine hepatocytes.  At 3 weeks post transplant, AFC8/DKO mice had higher levels of 
human albumin levels in the blood compared to DKO mice (Fig. 3.5B).  Human CD34+ 
cells (HSC) and hepatocyte progenitor cells (Hep) were isolated from the same human 
donor fetal liver, and injected into the liver of irradiated newborn DKO and AFC8/DKO 
mice.  Mice were then injected with AP20187 to induce damage of the mouse liver (Fig. 
3.4).  Mice were bled 12-15 weeks post transfer (wpt) to measure human albumin levels 
and human immune cell engraftment in the blood.  We observed a significant increase of 
albumin levels in AFC8/DKO-hu HSC/Hep mice compared to DKO-hu HSC/Hep mice 
 (Fig. 3.5A).   
Increased engraftment of hepatocytes in AFC8/DKO-hu HSC/Hep mice was also 
demonstrated by immunohistochemistry (IHC) staining for human albumin in the liver 
(Fig. 3.5D).  Human albumin + cells were counted in multiple fields of stained sections at 
4x magnification, and we determined the average reconstitution to be ~17% in > 10 mice 
(Fig. 3.5C).  We further tested whether the human hepatocytes were differentiated into 
mature hepatocytes.  We isolated RNA from the liver of control (untransplanted  
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Figure 3.4. Generation of AFC8/DKO-hu HSC/Hep mice. The caspase 8-FKBP fusion 
gene is driven by the liver-specific albumin enhancer/promoter (AFC8), and was used to 
create transgenic mice on the Rag2-/- γc-/- (DKO) background.  CD34+ human 
hematopoietic stem/progenitor cells (HSC) and human hepatocyte progenitor cells (Hep) 
isolated from the same donor human fetal liver are transplanted into the liver of irradiated 
AFC8/DKO new born mice.  A human immune system develops in all lymphoid organs 
including the liver.  The chemical dimerizer AP20187 causes dimerization/activation of 
caspase 8 through interaction of adjacent FKBP binding sites, which induces apoptosis of 
mouse hepatocytes and allows for liver regeneration with human liver cells.  
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Figure 3.5. Increased human albumin in blood and liver of AFC8/DKO mice. (A) 
Increase of human albumin in the blood of AFC8/DKO transplanted with human 
HSC/Hep (n = 13 per group, ** P < 0.01) or (B) adult hepatocytes (n = 17 per group, ** 
P < 0.01) and treated with AP20187.  (C) Liver sections from DKO mice without 
transplant (left) and both DKO (middle) and AFC8/DKO (right) transplanted with human 
HSC/Hep were stained with an anti-human albumin antibody.  Human hepatocytes were 
located around the veins and dispersed throughout all lobes of the liver.  (D) Human 
albumin positive cells were counted in two 4x fields and the percentage of positive cells 
was calculated (n = 16 mice per group, ** P < 0.01).  Liver RNA was isolated from 
AFC8/DKO mice with no transplant (control), AFC8/DKO-hu HSC/Hep (Hep) mice,  
and adult hepatocyte transplanted AFC8/DKO mice (Adult Hep.)  Quantitative real time 
PCR was performed and further demonstrates (E) human albumin in the liver.  Human 
liver metabolism enzymes (F) UGT2B7, (G) Cyp2C9, (H) Cyp2E1 are lower in Hep mice 
indicating the immature developmental status of the hepatocytes. Values shown are 
relative gene expression normalized to GAPDH. Data represent means ± s.e.m. * P < 
0.05  
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AFC8/DKO), hepatocyte progenitor cell (Hep) transplanted, and adult hepatocyte 
transplanted AFC8/DKO mice (Adult Hep) for human hepatocyte-specific gene 
expression analysis.  We observed higher expression of human hepatocyte-specific genes, 
such as albumin, in Hep transplanted mice (Fig. 3.5E).  However, lower expression of 
mature hepatocyte genes CYP2E1, CYP2C9 and UGT2B7 was detected in AFC8/DKO-
hu HSC/Hep mice (Fig. 3.5F-H).  These results suggest that the transplanted Hep may not 
be fully differentiated into mature hepatocytes as adult hepatocytes. 
In addition to the engraftment with human hepatocytes, we were interested in the 
ability of AFC8/DKO mice to be repopulated with a human immune system.  
AFC8/DKO-hu HSC/Hep mice generated a full human immune system in all lymphoid 
organs (data not shown), including the liver (Fig. 3.6A,B).  Intriguingly, we observed 
significantly more human CD45+ leukocytes in the blood of AFC8/DKO-hu HSC/Hep 
when compared to non-transgenic DKO-hu HSC/Hep littermates (Fig. 3.7).  In summary, 
we have established a humanized mouse model with inducible liver damage that can be 
repopulated with a human immune system and chimeric human liver.   
 
AFC8/DKO-hu HSC/Hep mice can be persistently infected with clinical HCV 
isolates 
To determine if AFC8/DKO-hu HSC/Hep mice can be infected with HCV, we 
inoculated three cohorts of mice, including 9-12 mice per cohort, with two different 
clinical HCV isolates (genotype 1) or control human serum.  We monitored HCV viral 
load in the serum throughout the course of infection (up to 110 days), and detected virus  
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Figure 3.6. Human immune reconstitution in the liver of AFC8/DKO-hu HSC/Hep 
mice. (A)  Detection of human CD45+ leukocytes by IHC in the liver of AFC8/DKO 
mice after transplant with human HSC + Hep. (B)  Intrahepatic leukocytes in the liver of 
AFC8/DKO-hu HSC/Hep mice were isolated and analyzed by FACS.  The cells were 
stained with the following human antibodies to detect surface markers; CD45, CD3, 
CD4, CD8, CD25, CD16, CD56, mouse CD45, LD7 (live/dead) marker.  Representative 
dot plot are shown.  The cells in each plot were first gated on the human cell population 
indicated above the plot, then analyzed as shown. 
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Figure 3.7. Enhanced human immune engraftment in AFC8/DKO-hu HSC/Hep 
mice.  Both DKO and AFC8/DKO littermates were transplanted with 0.5-1x106 human 
HSC and Hep.  After 12-15 weeks, mice were bled and human immune reconstitution 
was determined by staining blood lymphocytes with surface markers, including human 
(h) CD45, mouse (m) CD45, and VLD live/dead marker, for FACS analysis.  (A) 
Representative dot plot from transplanted DKO and AFC8/DKO mice gated on human 
CD45+ cells.  (B) Graph of summarized data for the percentage of human CD45+ cells in 
the blood of transplanted DKO and AFC8/DKO mice.  Data are representative of n=16 
mice per group with the mean ± s.e.m. * P < 0.05  
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in the serum of a few but not all mice (data not shown).  To determine if we could detect 
HCV in the liver tissue, immune responses to the virus, and liver pathology, we sacrificed 
mice at multiple intervals 32-110 dpi.  We isolated RNA from the liver of mock and 
HCV infected mice and used quantitative real time PCR to detect HCV RNA.  We 
detected HCV RNA in the liver of 7 out of 14 mice analyzed, with a representative cohort 
shown (Fig. 3.8A).  Importantly, we did not detect HCV RNA in AFC8/DKO mice with 
no human cell transplant (TP) that were inoculated with HCV (Fig. 3.8A).   
When ALT levels were measured, significant induction of ALT was detected in 
HCV infected AFC8/DKO-hu HSC/Hep mice (Fig. 3.8C).  Next, we characterized liver 
pathology associated with HCV infection.  In several HCV infected mice, but not mock 
or no TP mice, we observed significant leukocyte infiltration into the liver, with three 
representative HCV infected mice shown (Fig. 3.8B).  To distinguish the cellular 
infiltrate, we analyzed liver leukocytes by FACS.  We observed an increase of all human 
leukocyte subsets including CD4, CD8 T cells, human regulatory T cells (CD4+ CD25+), 
natural killer (CD56+ CD3-), and plasmacytoid dendritic cells (CD123+ CD4+) in the 
liver of HCV infected mice (Fig. 3.8D-H), corresponding to what is often observed in 
HCV infected humans (29-31).   
 
HCV infection induces HCV-reactive human immune responses 
To further characterize the human immune response in HCV infected mice, we 
mixed splenocytes and mesenteric lymph nodes (mLN) isolated from mock or HCV 
infected mice and stimulated them with phytohaemagglutinin (PHA).  We measured 
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Figure 3.8. AFC8/DKO-hu HSC/Hep mice can be persistently infected with patient 
HCV isolates, leading to human immune infiltration and liver injury.  (A) HCV 
RNA detected in the liver of AFC8/DKO-hu HSC/Hep mice inoculated with a clinical 
HCV isolate genotype 1.  RNA was isolated from the liver of mock and HCV infected 
mice, and HCV RNA was detected by quantitative real time PCR.  Values represent HCV 
RNA/ ug liver tissue relative to GAPDH. Data shown are from one cohort of infected 
mice and represent ± s.d. between duplicate samples. * P < 0.05, ** P < 0.01.  (B) 
Leukocyte infiltration into the liver of HCV infected mice.  Liver sections were stained 
with H&E.  No leukocyte infiltration was observed in mock, AFC8/DKO-hu HSC/Hep 
inoculated with control sera, or untransplanted mice inoculated with HCV. (C) ALT 
analysis of serum from HCV and mock infected mice. Data represent mean ± s.e.m from 
n = 6 mice per group. * P < 0.05 
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Figure 3.8, continued. (D-H) FACS analysis of intrahepatic human leukocytes from 
Mock and HCV infected mice.  Average cell number of the indicated populations is 
shown.  Data represent mean ± s.e.m from n = 6 mice per group. 
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human effector cytokines, including IL-2, IFN-γ, and TNF-α, in human CD4+ and CD8+ 
T cells by intracellular FACS staining.  Notably, we observed a significant increase of all 
cytokines in both CD4+ (Fig. 3.9A) and CD8+ (Fig. 3.9B) human T cells from HCV 
infected mice compared to mock, indicating that T cells from HCV infected mice were 
primed.  
To determine HCV specific immune responses, we stimulated the 
splenocyte/mLN mixed cells from mock and HCV infected mice with an overlapping 
peptide pool from the HCV core region + anti-CD28 mAb.  We cultured the cells for 8 
days, re-stimulated with the HCV peptide pool for 18h, and then analyzed cell number 
and immune responses.  Strikingly, we observed a 4-5 fold expansion of CD45+ human 
leukocytes (Fig. 3.9C), mostly human CD3+ T cells (Fig. 3.9D), in HCV infected mice 
relative to mock mice.  Expanded human T cells from HCV infected mice also produced 
significantly more human IFN-γ, measured by Elispot (Fig. 3.9E), as well as IL-2, IFN-γ, 
and TNF-α, in human CD4+ (Fig. 3.9F) and CD8+ T (Fig. 3.9G) cells when analyzed by 
intracellular FACS staining.  These results demonstrate that HCV infected AFC8/DKO-
hu HSC/Hep mice induced specific human T cell responses to HCV antigens. 
 
AFC8/DKO-hu HSC/Hep mice develop liver fibrosis after HCV infection 
Since chronic liver inflammation in humans infected with HCV often leads to 
liver fibrosis, we assessed the degree of liver damage in mock and HCV infected 
AFC8/DKO-hu HSC/Hep mice.  We further confirmed an increase of human leukocyte 
infiltration into the liver HCV infected mice by IHC staining for human CD45+  
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Figure 3.9. HCV infection induces HCV-reactive human immune responses.  
Increase of effector cytokines in HCV infected AFC8/DKO-hu HSC/Hep mice.  
Splenocytes and mesenteric lymph nodes from mock and HCV infected mice were 
isolated, mixed, and stimulated for 20 hours with 10ug/ml PHA.  The cells were stained 
with antibodies for human T cells (CD3+, CD4+, CD8+) and for intracellular human IL-2 
IFN-γ, and TNF-α.  Cells were gated on human CD45+ CD3+, then on either (A) CD4+ 
or  
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Figure 3.9, continued. (B) CD8+.  Numbers represent the % cytokine + of CD4+ or 
CD8+.  A representative FACS plot and summarized data is shown for each cell 
population.  Data represent mean ± s.e.m from two cohorts of mice with n = 4 per group. 
* P < 0.05, ** P < 0.01, *** P < 0.001.  
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Figure 3.9, continued. (C,D) Expansion of human T cells from HCV infected mice after 
stimulation with an HCV Core peptide pool.  Splenocytes and mesenteric lymph nodes 
from mock and HCV infected AFC8/DKO-hu HSC/Hep mice were isolated, mixed, and 
stimulated with a pool of 19 HCV Core peptides at 10ug/ml each + 1ug/ml anti-CD28 
mAb.  The cells were then cultured for 8 days, re-stimulated overnight, then counted and 
stained with human CD3 and CD45.  Fold increase of (C) CD45+ and (D) CD3+ cells 
from HCV infected mice was calculated relative to mock cells set as 1. Expanded cells 
were also re-stimulated with the same HCV Core peptide pool for 18 hours to detect (E) 
human IFN-γ by Elispot  
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Figure 3.9, continued. or were stained with antibodies for human T cells (CD3+, CD4+, 
CD8+) and for intracellular human IL-2 IFN-γ, and TNF-α.  Cells were gated on human 
CD45+ CD3+, then on either (F) CD4+ or  
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Figure 3.9, continued. (G) CD8+.  Numbers represent the % cytokine + of CD4+ or 
CD8+.  A representative FACS plot and summarized data is shown for each cell 
population.  Data represent mean ± s.e.m from two cohorts of mice with n = 4 per group. 
* P < 0.05, ** P < 0.01, *** P < 0.001.  
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(Fig. 3.10 upper panel).  While mock and AFC8/DKO mice without human TP did not 
develop fibrosis, HCV infected mice had significant portal fibrosis as well as bridging 
fibrosis with numerous septa throughout the liver parenchyma (Fig. 3.10 lower panel).  
Human CD45+ cells often localized to the same area as the fibrotic regions, indicating a 
human immune mediated liver damage.  
Since activated hepatic stellate cells are known to be responsible for promoting 
liver fibrosis in HCV infection (3), we stained liver sections with α-smooth muscle actin 
to detect activated stellate cells.  We observed increased activated stellate cells in the 
liver of HCV infected mice, and often in areas with significant fibrosis (Fig. 3.11A).  To 
further confirm the fibrosis, we analyzed the expression of human genes involved in liver 
fibrosis.  Activated hepatic stellate cells secrete extracellular matrix proteins (eg. 
Col1A1), which results in fibrosis that can progress to cirrhosis and ultimately HCC (32).  
Additionally, activated stellate cells also express TIMP1 to inhibit MMPs, the 
degradation of extracellular matrix, and fibrosis resolution (33).  Results from this study 
shows induction of the matrix modulator TIMP1 (Fig. 3.11B), and extracellular matrix 
protein COL1A1 (Fig. 3.11C) in HCV infected humanized mice but not in mock or non-
transplanted HCV inoculated animals, with relative gene expression normalized to human 
GAPDH.  These results suggest that, in HCV infected AFC8/DKO-hu HSC/Hep mice, 
human stellate cells were activated to produce collagens and inhibitors of extracellular 
matrix, leading to the induction of liver fibrosis. 
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Figure 3.10. AFC8/DKO-hu HSC/Hep mice develop liver fibrosis after HCV 
infection. Representative liver sections from AFC8/DKO-mock, AFC8/DKO- hu 
HSC/Hep-mock, AFC8/DKO-no transplant + HCV, and three AFC8/DKO- hu HSC/Hep 
+ HCV were stained with antibodies for anti-human CD45 (top panel), to detect human 
leukocyte infiltration, and Sirius Red/Fast Green (bottom panel) to visualize liver 
fibrosis.  Infiltration of human CD45+ leukocytes and bridging fibrosis with numerous 
septa was observed in many HCV infected mice.   
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Figure 3.11. Liver fibrosis correlates with increased activated stellate cells and 
human fibrotic genes. (A) Representative liver sections from AFC8/DKO-mock, 
AFC8/DKO-hu HSC/Hep-mock, AFC8/DKO-no transplant + HCV, and three 
AFC8/DKO-hu HSC/Hep + HCV were stained with an antibody for α-smooth muscle 
actin to visualize activated stellate cells.  Human specific fibrotic gene expression profile 
of (B) TIMP1 and (C) COL1A1 was examined in the liver using quantitative real time 
PCR. Values shown are relative gene expression normalized to human GAPDH.  Data 
represent mean ± s.e.m.  
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Discussion 
 
We report here the first humanized mouse model to contain both a human 
immune system and liver.  The AFC8/DKO model enables us to inducibly damage 
murine hepatocytes, without bystander cell killing.  We transplanted AFC8/DKO mice 
with human CD34+ HSC and fetal liver-derived hepatocyte progenitors.  As expected, 
they developed a functional human immune system in all lymphoid organs, including the 
liver.  AFC8/DKO-hu HSC/Hep mice were also efficiently repopulated with human 
albumin+ liver cells after induction of liver damage.  AFC8/DKO-hu HSC/Hep mice 
were susceptible to HCV infection and induced HCV-specific human immune responses, 
leading to liver fibrosis.   
Several other groups have reported humanization of the liver in mice by depleting 
mouse hepatocytes through expression of a constitutively cytotoxic transgene in the liver, 
allowing transplanted human hepatocytes to have a growth advantage and re-populate the 
liver (7-15).  However, these mice have disadvantages including neonatal death, 
transgene toxicity, and lack of regulation of liver damage in Alb-uPA mice, or the need 
for additional chemicals/viruses in FRG mice.  Highlighting the deficiencies in both of 
these models is the lack of a human immune system.  To overcome these deficiencies, we 
created AFC8/DKO mice.  The AFC8/DKO model enables us to inducibly damage 
murine hepatocytes through a natural death mechanism, without bystander cell killing.  In 
addition, the immunodeficient DKO mouse on the BALB/c background permits efficient 
engraftment of human cells including human immune cells.   
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It has been reported that immature hepatocytes express high levels of human 
hepatocyte-specific genes such as albumin, but low levels of mature hepatocyte genes 
CYP2E1, CYP2C9 and UGT2B7 (34) (35).  We tested whether the transplanted liver 
progenitors isolated from human fetal liver had differentiated into fully mature 
hepatocytes.  Human hepatocytes from AFC8/DKO-hu HSC/Hep mice appeared to 
express high levels of albumin, but relatively low levels of CYP2C9 and UGT2B7.  
These data suggest that the transplanted human hepatocyte progenitor cells may not be 
fully differentiated into mature hepatocytes, which could account for the relatively low 
albumin in the blood.   
  To test whether AFC8/DKO-hu HSC/Hep mice were susceptible to HCV 
infection, we inoculated three cohorts of mice with two different clinical isolates of HCV 
genotype 1 or control human sera.  We were able to detect HCV RNA in the liver of 
AFC8/DKO-hu HSC/Hep mice when sacrificed 32-110dpi (Fig. 3.8A).  Demonstrating 
the necessity of human hepatocytes for HCV infection, we did not detect HCV RNA in 
the liver of inoculated AFC8/DKO mice that were not transplanted with human cells.  
Since we detected HCV in the serum of only a few mice (data not shown), it is possible 
that the relative low level of human hepatocyte engraftment (15-20%), or the immature 
human hepatocytes may limit HCV replication and/or secretion into the blood.  
Alternatively, the human immune system may have mounted a response and reduced the 
virus replication.  Support for this hypothesis came when we examined the liver 
pathology and immune cell infiltrate in mock and HCV infected mice.  We observed 
significant leukocyte infiltration into the liver of HCV infected mice (Fig. 3.8B), that was 
enriched with T cells, NK, and pDC’s (Fig. 3.8D,E,G,H), which are known to be 
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involved in controlling HCV in humans (30, 31).  Additionally, there was an increase in 
ALT levels only in infected mice containing a human immune system (Fig. 3.8C and data 
not shown). 
We further characterized the human immune response to HCV with spleen and 
mLN cells.  After short term PHA stimulation, significantly more human effector 
cytokines, including IL-2, TNF-α, and IFN-γ, were produced in both CD4+ (Fig. 3.9A) 
and CD8+ (Fig. 3.9B) human T cells from HCV infected mice, compared to mock.  This 
indicates that T cells from HCV infection induced T cell responses, although it did not 
demonstrate HCV-specific immune responses.   
HCV specific T cell responses have been previously demonstrated by stimulation 
of lymphocytes from human patients infected with HCV (36).  More robust immune 
responses are observed in patients that clear the virus during the acute infection (37), 
rather than those who progress to chronic infection (38).  We tested for specific immune 
responses to HCV by stimulating cells with a pool of HCV overlapping peptides from the 
core region (36).  Not only did we observe a 4-5 fold expansion of T cells from HCV 
infected mice, compared to mock (Fig. 3.9C-D), the T cells also elicited enhanced 
effector responses through production of IL-2, TNF-α and IFN-γ (Fig. 3.9E-G).  
Therefore, HCV infection induced HCV-specific human T cell responses in AFC8/DKO-
hu HSC/Hep mice.  Our future effort will focus on characterizing the human immune 
responses in relation to HCV control and disease progression. 
Immune responses against HCV are also implicated as mediators of liver injury 
(39).  HCV infected AFC8/DKO-hu HSC/Hep mice often developed liver fibrosis not 
only at the portal areas, but more strikingly with bridging fibrosis with numerous septa 
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throughout the liver parenchyma (Fig. 3.10).  We showed that HCV infection led to 
increased level of activated stellate cells in fibrotic livers (Fig. 3.11A).  Furthermore, 
human extracellular matrix protein COL1A1, and inhibitor of matrix degradation TIMP1 
were induced in some HCV infected liver.  Therefore, HCV infection induced liver 
fibrosis in AFC8/DKO-hu HSC/Hep mice, and both the resulting extracellular matrix and 
collagen degradation inhibitor were expressed from human cells.  It is of interest that the 
corresponding mouse fibrosis-associated genes were not induced by HCV infection.  A 
species-specific mechanism appears to be involved.  Future effort will be necessary to 
elucidate the mechanisms. 
In summary, we have established a humanized mouse model with inducible liver 
damage that can be repopulated with a human immune system and chimeric human liver.  
AFC8/DKO-hu HSC/Hep were susceptible to HCV infection, which developed human T 
cell responses to HCV, and liver pathology including hepatitis and fibrosis.  In addition to 
studying HCV infection and pathogenesis, AFC8/DKO-hu HSC/Hep can be used to study 
other liver-tropic pathogens such as HBV and malaria.  Since HCV/HIV co-infection 
occurs in nearly 25% of patients (40), and often leads to end-stage liver disease (41) there 
is a significant need for a model system to study co-infection of these viruses.  Anti-viral 
drugs, vaccines, and immunotherapies can also be tested AFC8/DKO-hu HSC/Hep mice 
to clear or prevent viral infection.  Additionally, drug metabolism and interaction with the 
immune system can be investigated, since drug induced liver injury (DILI)  is a serious 
complication for many drugs in development, which can result in fulminant liver failure 
(42).  Therefore, the AFC8/DKO-hu HSC/Hep mouse model may shed light on many 
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different fields to make new and exciting discoveries that were previously limited by lack 
of a robust animal model with both human immune system and human liver. 
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Purpose and scope 
With hundreds of millions of people worldwide chronically infected with HCV, 
often leading to liver fibrosis and cancer, HCV poses a significant global health threat.  
Current therapies to combat HCV are often limited by low efficacy and poorly tolerated 
side effects.  In search for an improved therapy to eradicate a persistent viral infection of 
the liver, I used LIGHT as an immunotherapy, which induced clearance of persistently 
expressed foreign antigens from an AAV vector in the liver of mice.  Since the species 
tropism of HCV is limited to humans and chimpanzees, progress in developing improved 
therapies has been limited.  In order to create a more robust model system, I developed 
the AFC8/DKO-hu HSC/Hep humanized mouse model, which can be repopulated with a 
human immune system and liver.  I studied HCV infection, immune responses, and liver 
pathogenesis using this mouse model.   Here, I will discuss the general conclusions and 
future directions of this research to develop improved therapies and models to study 
liver-tropic pathogens. 
 
Findings and implications 
 
Chapter II: LIGHT induces clearance of a persistent AAV infection in the liver 
In this chapter I demonstrated the potential of LIGHT as an immunotherapy or 
therapeutic vaccine to clear a persistent viral infection in the liver.  Similar to HCV, 
adeno-associated virus vectors (AAV) are able to establish persistent foreign antigen 
expression in the liver (1).  AAV vectors in the liver can functionally impair T cell 
responses against the transgene (2, 3), contributing to persistence in the liver without 
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clearance by the immune system.  HCV is also able to persist in the liver through evasion 
and impairment of the hosts immune system (4-12).  Using AAV as a model of persistent 
foreign antigen expression in the liver, I sought to restore the impaired immune responses 
and clear the AAV from the liver.   
 LIGHT, the TNF superfamily member, interacts with the LTβR (13) and HVEM 
(14) receptors.  LIGHT is a potent co-stimulator of T cell responses through activation of 
CD8+ T cells and production of IFN-γ (15, 16).  Injection of an adenoviral vector 
expressing LIGHT (Ad-LIGHT) into tumor tissue leads to generation of tumor-specific 
CTL and rejection of both established and disseminated metastasizing tumor cells in the 
peripheral tissues of mice (17), demonstrating the therapeutic potential of LIGHT in 
reversing tolerance.   
The relevance of this pathway to immune responses in the liver has also been 
demonstrated.  In the liver, LTβR is expressed on hepatocytes and Kupffer cells, where it 
contributes to liver regeneration and liver homeostasis and T cell responses (18, 19).  
Additionally, blocking LTβR signaling reduced inflammation in the liver of transgenic 
mice expressing LTα-β (20).  In relevance to HCV, the core protein of HCV directly 
interacts with LTβR, which may contribute to HCV-induced liver diseases (21).  Since 
the LIGHT/LTβR-HVEM signaling pathway is involved in modulation of immune 
responses in the liver, we hypothesized that the T cell tolerance induced by hepatic 
infection of AAV may be reversed by LIGHT treatment promoting clearance of the AAV 
in the liver. 
I demonstrated that liver-tropic AAV8 expressing GFP established long-term 
persistent expression in the liver of mice, without inducing liver inflammation.  Now with 
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a persistent AAV expression model system in place, I tested whether LIGHT could 
reverse the T cell tolerance and clear the AAV from the liver. After establishing 
persistent AAV-GFP expression in the liver, I treated mice with Ad-LIGHT or a control 
Ad.  Mice treated with Ad-LIGHT had complete clearance of GFP expression by AAV in 
the liver, with only minimal GFP loss in Ad-Ctrl vector treated mice.  Strategies to 
eliminate Ad vector associated immune responses will be discussed in future directions.  
We proved that LIGHT played a critical role in Ad-LIGHT mediated clearance of AAV.  
When the LTβR-Ig fusion protein was added to the treated mice it blocked the ability of 
Ad-LIGHT to clear AAV.  LTβR-Ig acts as a soluble receptor to LIGHT, thereby 
inhibiting LIGHT binding to its receptors.  Thus, the immune responses generated to the 
Ad vector alone were not enough to clear the AAV, and LIGHT binding to its receptors 
was necessary.  
To determine the mechanism of the Ad-LIGHT-mediated clearance of AAV, I 
examined liver inflammation and immune responses in the mice.  Ad-LIGHT treated 
mice had significant infiltration of leukocytes into the liver.  To distinguish what immune 
cells were increased in the LIGHT treated mice, I analyzed leukocytes isolated from the 
liver and spleen.  There was a significant increase of activated T cells with effector 
function in both the liver and spleen in Ad-LIGHT treated mice compared to Ad-Ctrl.  
These results were consistent with the role of LIGHT as a co-stimulator of CD8+ T cells 
to produce IFN-γ production.  Additionally, these results imply that LIGHT has the 
ability to help overcome T cell tolerance in the liver by re-activation of the immune 
system. While the activation of effector T cell responses in Ad-LIGHT treated mice 
certainly contributed to the clearance of AAV, they were not necessarily antigen specific 
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responses.  Strategies to tailor LIGHT therapy towards specific antigens will be discussed 
in future directions. 
Since the effects of LIGHT are induced through its interaction with the LTβR 
and/or HVEM receptors, the role of each receptor in liver inflammation and AAV 
clearance was analyzed.  Knockout mice for each receptor were utilized to dissect these 
effects.  Interestingly, Ad-LIGHT led to clearance of AAV in wild type and both mutant 
mice, suggesting that neither LTβR nor HVEM alone was critically required for LIGHT-
mediated AAV clearance.  It is likely that they are redundantly involved in mediating 
LIGHT induced AAV clearance.  Alternatively, a third unidentified LIGHT receptor may 
be involved.  Preliminary results show that LIGHT can efficiently stimulate HVEM-null 
T cells.  As LTβR is not expressed on T cells, the results suggest the presence of a novel 
LIGHT receptor on T cells.  Further evidence for a novel LIGHT receptor was shown 
when NK cells were directly activated by LIGHT (22).  To identify the receptor, a yeast 
two hybrid screen can be performed using LIGHT as the bait and a library of cDNA from 
T and NK cells as the prey.  
The liver of LTβR and HVEM null mice was also examined for inflammation and 
leukocyte infiltration.  Intriguingly, while Ad-LIGHT infected wild type and HVEM-null 
mice developed liver inflammation and lymphocyte infiltration, only a low ALT 
induction with no significant leukocyte infiltration into the liver of LTβR-null mice 
treated with Ad-LIGHT was observed.  Therefore, the LTβR is required for LIGHT-
mediated liver inflammation and injury, but not for its AAV clearance activity.  
Strategies to utilize LIGHT therapeutically without inducing liver inflammation will be 
discussed in future directions.  In conclusion, treatment with LIGHT induced T cell 
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responses and liver inflammation via interaction with its receptors, leading to the 
clearance of AAV from the liver, thereby demonstrating the potential of LIGHT 
treatment to clear liver-tropic viruses.  
 
Chapter III: Creation of AFC8/DKO-hu HSC/Hep mice and characterization of 
HCV infection, immune responses, and pathogenesis. 
Now that I had characterized LIGHT as an immunotherapy to clear AAV from the 
liver, I sought to develop a model to study HCV infection, with the ultimate goal of using 
LIGHT to clear a persistent HCV infection.  However, understanding HCV infection, 
immunopathogenesis, and development of improved therapies for HCV is hampered by 
the lack of a robust model system.  Due to limited species tropism, the current animal 
models to study HCV include chimpanzees and mice with chimeric human livers.  
However, the lack of liver disease progression, as well as ethical and monetary concerns 
limits the use of chimpanzees. Additionally, the available humanized mice contain either 
human liver cells or a human immune system but no model contains both.  Since HCV 
infects the liver, and the immune system is a critically involved in both preventing HCV 
infection and causing liver disease progression, the lack of a model containing both is a 
glaring deficiency in currently available humanized mice.  To overcome this deficiency, I 
describe in chapter III the development of the AFC8/DKO-hu HSC/Hep humanized 
mouse model containing both a human immune system and liver.  Next, I demonstrate 
that AFC8/DKO-hu HSC/Hep are susceptible to HCV infection, develop human immune 
responses to HCV, and develop liver fibrosis after HCV infection. 
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To create AFC8/DKO-hu HSC/Hep mice, I utilized a system of targeted, 
inducible activation of caspase 8, allowing for cell death through the natural apoptotic 
pathway, rather than inducing hepatocyte necrosis through expression of toxic genes as 
demonstrated in other model systems (23-25). Testing this system in vitro confirmed 
targeted killing of hepatocytes, with no bystander cell death.  Since this system was 
designed to destroy mouse hepatocytes, which were in contact with the human 
hepatocytes I was attempting to expand, the specificity of cell killing is essential for this 
system to work.    
After transplanting AFC8/DKO mice with human HSC and Hep they developed a 
full and functional human immune system throughout all lymphoid organs, including the 
liver.  An exciting, yet unexplained, finding was that AFC8/DKO mice developed a more 
robust immune system, as measured by human CD45 in the blood, when compared to 
littermate DKO mice transplanted with the same cells.  While the mechanism for this 
beneficial caveat has not yet been determined, I foresee two likely possibilities.  One, 
there is a low level of leaky expression of the caspase 8 transgene in the liver, leading to 
depletion of mouse hepatocytes without injection of the dimerization drug.  Since the 
early hematopoiesis of the CD34+ transplanted human stem cells occurs in the mouse 
liver, there is more room for the cells to expand and differentiate into human immune 
lineages.  A second possibility could be due to the insertion site of the transgene.  If the 
transgene insertion site disrupts development of any mouse immune lineage remaining in 
the DKO mice, such as neutrophils or macrophages, there would be fewer mouse cells 
capable of interfering with the transplanted human cells. 
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Next, I demonstrated that, upon induction of liver damage, AFC8/DKO-hu 
HSC/Hep mice can be repopulated with human albumin + liver cells.  While there were 
significant amounts of human albumin + cells dispersed throughout the liver parenchyma 
as observed by IHC and when measured by quantitative real time PCR, there were 
relatively low levels of human albumin secreted into the blood.  Since the transplanted 
Hep were isolated from human fetal liver, they may not have evolved into mature 
hepatocytes with the ability to efficiently secrete albumin.  In addition to xenobiotic 
metabolism, one of the main functions of the liver is to secrete proteins that are critical 
for maintaining systemic osmotic pressure and transport of various molecules (26).  
Differentiation of hepatocytes to carry out these functions is characterized by the 
induction of xenobiotic metabolism enzymes (CYP450s, UGTs) and serum proteins 
(Albumin) (27).  Phase I metabolism by CYP450s are generally followed by phase II 
metabolism and excretion, and UGT2B7 is a major phase II metabolism enzyme in the 
liver.  Examination of liver RNA from Hep transplanted mice indicated higher expression 
of human hepatocyte-specific genes such as albumin, but lower expression of mature 
hepatocyte genes CYP2E1, CYP2C9 and UGT2B7 (28).  Therefore, while the 
transplanted human hepatocyte progenitor cells are abundant in the liver, they do not 
appear to be fully differentiated into mature hepatocytes, which may be inhibiting 
efficient transport of albumin into the serum.   Strategies to enhance hepatocyte growth 
and differentiation will be discussed in future directions. 
Now having equipped AFC8/DKO-hu HSC/Hep mice with both a human immune 
system and liver, they were primed to be infected with HCV to study immune responses 
and pathogenesis.  Two different genotype 1 clinical isolates of HCV were used to infect 
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multiple cohorts of mice.  Upon sacrifice of the mice, HCV RNA was detected in the 
liver of ~50% of inoculated mice, but only a few mice had detectable HCV in the sera.  
Since these mice are equipped with a human immune system, it is likely that an immune 
response was induced to clear the HCV.   Supporting this hypothesis was the abundance 
of T cells, pDC’s and NK cells that had infiltrated into the liver of HCV inoculated mice, 
which are known to be involved in HCV clearance in humans (11, 29).  It will be 
interesting to further dissect the immune cell infiltrate into the liver of HCV infected 
mice, such as the IFN producing capacity of the pDC’s and Kupffer cell accumulation in 
the liver. 
With preliminary evidence of a human immune response to HCV, I set out to 
further unravel this exciting result.  A pool of overlapping peptides from the core protein 
of HCV was used to stimulate spleen/mLN cells from mock and HCV infected mice.  We 
observed antigen specific expansion of T cells from HCV infected mice with enhanced 
effector capacity.  Since the core peptides are from a structural region of the virus, it is 
possible that the immune responses were generated by the initial inoculated virus, and not 
replicating virus.  To determine this, we can use peptides from the NS3-4A non-structural 
region of the virus to stimulate cells, since virus replication is required for exposure of 
those antigens.  The ability of AFC8/DKO-hu HSC/Hep mice to generate human immune 
responses to HCV demonstrates the vast potential of this model for HCV immunology 
research, and additional future directions in this realm will be discussed later.    
Although immune responses against HCV may clear the virus, they are also 
implicated as mediators of  liver injury (30).  To characterize the liver pathology in 
AFC8/DKO-hu HSC/Hep mice, the liver was analyzed for markers of fibrosis.  
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Strikingly, HCV infected mice developed bridging liver fibrosis throughout the liver 
parenchyma.  Advanced bridging fibrosis is characterized as cirrhosis and often leads to 
hepatocellular carcinoma (31).  Since this late stage parenchymal bridging fibrosis was 
only evident in infected mice with a human immune system, this pointed towards 
immune mediated liver injury.  While we detected late stage fibrosis in some mice, and 
possible adenoma development in one mouse, it will be interesting to let the infection 
progress even longer than our latest time point of 15 weeks and determine if cirrhosis and 
hepatocellular carcinoma develop, as is observed in humans.  
While liver fibrosis was evident, it was not immediately clear whether it was 
through damage of the transplanted human hepatocytes or the resident mouse liver cells.  
In search for the species origin of the liver damage, activated human stellate cells were 
identified to be increased in fibrotic livers of HCV infected mice, as well as human 
extracellular matrix protein Col1A1, and inhibitor of matrix degradation TIMP1.  It will 
be interesting to test additional human specific genes involved in fibrosis such as MMP 
and PDGF.  Additionally, since the liver damage appeared to be localized to human cells, 
and not mouse hepatocytes, it will be interesting to determine this species-specific 
induction of liver damage.  It is possible that there is inefficient signaling between mouse 
hepatocytes and human fibrotic genes, such as MMP, PDGF, and TIMP.  In conclusion, 
these results imply that the induction of fibrosis was human immune mediated and the 
resulting extracellular matrix that distinguished the fibrosis was of human origin.   
 
Future Directions 
 
 110 
Improved LIGHT therapy to clear persistent viral infections 
These studies present opportunities to not only improve the models described, but 
also use them to expand the knowledge of many other fields.  Here, I will discuss 
improvements to the model, as well as potential pitfalls to the model and strategies to 
overcome them.  As alluded to earlier, the use of the Ad vector to express LIGHT to clear 
AAV from the liver may augment the immune response by itself.  Since AAV is known 
to not induce a strong immune response (32, 33), the role of the Ad vector in inducing an 
immune response can be eliminated by expression of LIGHT using an AAV2 vector.  
Using an AAV2 vector, rather than AAV8, would further avoid any immune responses 
against AAV8.  Using AAV-LIGHT would address the role of the Ad vector in immune 
responses, but Ad-LIGHT still has potential as a therapeutic vector.  
Further improvements in LIGHT-mediated therapy will involve reducing the 
inflammation in the liver, while still clearing the persistent viral infection.  Since Ad-
LIGHT was able to clear AAV from the liver of LTβR-null mice with only a low ALT 
induction and no significant leukocyte infiltration into the liver, the LTβR is implicated 
in the liver inflammation.  Generation of a mutant LIGHT molecule that specifically loses 
interaction with LTβR would improve this system by providing a novel therapeutic that 
can clear a liver-tropic virus without liver injury.  Creation of this molecule can be 
achieved by constructing a library of structural mutations of LIGHT mutants by amino 
acid substitution, and screening the mutants for affinity to the LTβR and HVEM (34).  
While LIGHT induced broad CD8+ T cell responses correlating with clearance of 
AAV, the immune responses were not necessarily antigen specific.   By tailoring LIGHT 
with an antigen of the targeted virus, immune responses would be more specifically 
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directed to the virus.  Preliminary data suggests that LIGHT tethered to HBV antigens 
induces specific immune responses to clear HBV proteins in transgenic mice.  A similar 
approach can be used for HCV, by tethering HCV antigens to LIGHT to enhance immune 
responses and clear a persistent HCV infection. 
 
AFC8/DKO-hu HSC/Hep mice – further characterization and future applications 
The AFC8/DKO-hu HSC/Hep mouse model has enormous potential, enabling a 
broad range of scientific disciplines to further their understanding of human diseases and 
design novel therapies to improve human health.  First, I will discuss improvements to 
the model, followed by additional experiments to further characterize HCV infection in 
AFC8/DKO-hu HSC/Hep mice, and finally new uses for the model.   
 
Proposed improvements to the humanized mice 
 
While the AFC8/DKO-hu HSC/Hep mouse model provides a robust platform to 
advance the study of many human pathogens, I envision modifications to improve the 
model.  The level of human hepatocyte reconstitution can be improved upon.  While 
AFC8/DKO-hu HSC/Hep developed a nearly 20% humanized liver, the hepatocytes 
appeared to not be fully differentiated into mature hepatocytes.  Further differentiation 
and growth of the hepatocytes can be augmented by the addition of human hepatocyte 
growth factor (HGF) or its receptor c-met, which has been shown to improved hepatocyte 
survival in transplanted mice (35).  To allow for greater than 20% human hepatocyte 
engraftment, perhaps there needs to be increased mouse liver damage allowing even more 
space for the human hepatocytes to grow.  Development of a liver tropic AAV8 vector 
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expressing a toxic gene, such as Bim (36), from a mouse cell specific promoter (37) can 
be used to achieve this goal.  Another approach to improving human hepatocyte 
engraftment is to deplete remaining mouse immune components.  We can inhibit the 
mouse complement system by treatment of mice with the protease inhibitor nafamostat 
mesilate (Futan), which has improved engraftment in other models (25).  
A potential limitation of the current AFC8/DKO-hu HSC/Hep mouse model for 
broad use is the availability of human fetal liver tissue used to derive the stem cells and 
hepatocyte progenitor cells.  Due to legislative and ethical issues, fetal liver tissue may 
not be available to all labs around the world.  To overcome this, human stem cells may be 
used to derive both the hematopoietic stem cells and hepatocytes used to transplant the 
mice, providing an unlimited source of cells and further improving the reproducibility 
and robustness of the model.  Significant efforts are underway to advance the potential of 
both embryonic stem cells (ES) and induced pluripotent (iPS) stem cells.  While the exact 
protocols to differential these cells into HSC and hepatocytes are not fully established, 
significant progress recently (38-42) points towards an optimistic future for using ES or 
iPS derived stem cells in humanized mice. 
A vigorous and broad human immune response is also critical to this model.  
Although AFC8/DKO-hu HSC/Hep mice develop a fully functional immune system and I 
detected antigen specific immune responses to HCV, the immune response can be 
improved.  It is believed that the human T cell repertoire is selected in the context of the 
mouse MHC in the mouse thymus (43), limiting full characterization of MHC class I and 
MHC II restricted human T cell responses.  However, this can easily be overcome by 
transplanting human thymus and liver fragments under the kidney capsule, as has been 
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shown in other models (44), allowing for human T cell selection in the context of a 
human thymus.  
 
Liver leukocyte immune responses  
One of the most exciting findings upon infection of AFC8/DKO-hu HSC/Hep 
mice with HCV was the development of specific human T cell responses.  Splenocytes 
and mesenteric lymph nodes were stimulated with HCV peptides, leading to expansion 
and effector cytokine production.  Due to a limitation in the number and purity human 
liver leukocytes isolated, they were not used to measure specific T cell responses.  In 
future experiments, we can purify CD4+ and CD8+ T cells and stimulate them with HCV 
antigens.  It will be interesting to characterize their immune responses to HCV antigens 
due to the immediate proximity to infected cells in the liver.   
 
Humoral immune responses 
While cellular immune responses to HCV were extensively characterized, the 
humoral immune response has yet to be examined.  The role of the humoral immune 
response to HCV in humans is not completely clear.  During acute infection, antibodies 
do not appear to be required for viral clearance and neutralizing antibody production is 
significantly delayed (45).   However, studies in chimpanzees have demonstrated that 
neutralizing antibodies can provide partial protective immunity against HCV (46, 47).  
Therefore, it will be interesting to measure the levels of anti-HCV antibodies present in 
the serum of infected AFC8/DKO-hu HSC/Hep mice and determine the potential of these 
mice for vaccine studies.  HCV specific antibodies can be detected by ELISA or Western 
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blot by incubating serum from infected mice with HCV protein coated membranes, then 
probing with anti-human IgG and IgM.  
 
HCV infection verification 
Further characterization of the capacity of AFC8/DKO-hu HSC/Hep mice to be 
infected with HCV is needed.  To demonstrate transmission of HCV, serum or liver cells 
from infected mice can be injected into naïve AFC8/DKO-hu HSC/Hep mice.  While we 
infected mice with two different genotype 1 clinical isolates, it will be interesting to test 
the ability of other HCV strains, such as genotype 2a JFH1, to infect AFC8/DKO-hu 
HSC/Hep mice.  Additionally, detection of negative strand RNA and visualization of 
HCV non-structural proteins by in situ hybridization and immunofluorescence will 
solidify the presence of replicating HCV in the liver.   
 
Mechanism of rapid fibrosis induction 
Another exciting discovery from HCV infected AFC8/DKO-hu HSC/Hep mice 
was the relatively rapid progression to liver fibrosis.  In humans, fibrosis usually occurs 
many years after infection with HCV (48).  It is intriguing how these mice progress to 
advanced liver fibrosis so quickly.  While it appears that the immune system plays a role 
in the induction of fibrosis, since human immune cells localize to fibrotic regions and no 
parenchymal fibrosis was evident in mice lacking an immune system,  it will be 
interesting to further decipher how and why the human immune cells in the mice induce 
fibrosis so rapidly.  Further characterization of the human immune cells responsible for 
the fibrosis induction and progression can be addressed by isolating various immune cell 
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populations from infected mice and transferring them to naïve AFC8/DKO-hu HSC/Hep 
host mice to track fibrosis progression.  The roles of the various immune cells involved in 
the fibrosis, including T cells, kupffer cells, and stellate cells, can also be selectively 
depleted and further dissected.  
 
Prevention of HCV infection 
 Having characterized HCV infection, immune responses, and liver fibrosis 
progression, the next step will be to prevent infection and liver damage.  Specifically 
targeted anti-viral therapy to HCV (STAT-C) drugs are making their way through the 
clinical trial pipeline, with at least two drugs likely to be approved soon for use in 
humans (49).  STAT-C drugs can be used in AFC8/DKO-hu HSC/Hep to block initial 
HCV infection as well as clear established infections. 
 
Drug induced liver injury 
Although there is optimism for using STAT-C drugs against HCV, more than 15 
drugs in development were halted during clinical trials (49), often due to drug toxicity, 
which was not identified in pre-clinical testing due to lack of a robust animal model.  
There are significant species differences in liver metabolism enzymes and response to 
xenobiotic drugs, which are prominently found between humans, mice, and rats  (50).  
Since pre-clinical testing of xenobiotic drugs is often done in mice and rats, the results 
have limited relevance to humans.  Additionally, drug induced liver injury (DILI)  is a 
serious complication for many drugs in development, which can result in fulminant liver 
failure  (51).  Since DILI is often induced by the immune system (52), a model with both 
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a human liver and immune system is critical to understand all aspects of xenobiotic drug 
metabolism and associated liver toxicity, making the AFC8/DKO-hu HSC/Hep mouse 
model an ideal choice. 
 
Immunotherapies and vaccine testing 
   In addition to STAT-C agents, immunotherapies and vaccines hold the promise of 
stimulating the immune system to prevent or clear an established infection.  The field of 
vaccine development towards HCV has a long way to go, since the virus mutates rapidly, 
making it difficult to target the evolving viral epitopes.  Further inhibiting progress is the 
lack of an appropriate model to study viral evolution in the context of a functional human 
immune system.  The AFC8/DKO-hu HSC/Hep model will fill this void.  Additionally, 
one of the major long-term goals of this project was to utilize LIGHT as an 
immunotherapy to clear a persistent HCV infection.  Now that I have established the 
efficacy of LIGHT and the susceptibility of AFC8/DKO-hu HSC/Hep to be infected with 
HCV, it will be exciting to bring these ideas full circle. 
 
HCV and alcohol 
 Although chronic HCV infection alone often leads to advanced liver disease, the 
addition of other agents, such as alcohol, greatly accelerates the disease.  The synergy of 
HCV and alcohol are responsible for more than two thirds of all liver disease in the 
Western world, through rapid onset of fibrosis and HCC (53).  Since the mechanism of 
how these two agents work together to accelerate liver disease is not fully understood, the 
AFC8/DKO-hu HSC/Hep model can be used to gain insight into the mechanism. 
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HIV/HCV co-infection 
 Another factor contributing to advanced liver disease in HCV infected patients is 
co-infection with HIV.  Due to similar routes of transmission, nearly 25% of patients are 
co-infected with HCV/HIV (54), often inducing advanced liver fibrosis and cirrhosis, 
leading to earlier mortality than HCV mono-infected patients (55).  Since HIV infects 
CD4+ immune cells and HCV infects hepatocytes, the AFC8/DKO-hu HSC/Hep mouse 
model provides an environment to study both of these viruses and how they 
synergistically induce accelerated liver disease progression. 
 
HBV, malaria 
 The AFC8/DKO-hu HSC/Hep mouse model can also be used to study other liver-
tropic pathogens such as HBV and the malaria parasite.  While a vaccine for HBV does 
exist, maternal transmission is still a significant threat to transmission.  Additionally, 
anti-viral therapies are not able to completely clear HBV (56).  Using the AFC8/DKO-hu 
HSC/Hep mouse model will advance the field of HBV research to identify novel 
therapeutics.  In addition to HBV, the transmissible malaria parasite, Plasmodium 
sporozoites,  utilizes liver resident kupffer cells as a portal to subsequently infect 
hepatocytes (57).  With human kupffer cells, hepatocytes, and a functional immune 
system, the AFC8/DKO-hu HSC/Hep mouse model will serve as an excellent host to 
study malaria.    
In conclusion, the AFC8/DKO-hu HSC/Hep mouse model will greatly advance 
the study of HCV infection, immunopathogenesis, and development of improved 
therapies to combat infection and liver disease progression.  Not only will this model 
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advance the study of HCV, but many other fields including HIV/HCV co-infection, 
HBV, malaria, drug induced liver injury, anti-viral drug testing, and vaccine development 
can utilize the AFC8/DKO-hu HSC/Hep mouse model to combat these complex health 
problems and improve human health.   
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